Thiazolopyridine derivatives as adenosine receptor antagonists
By developing thiazopyridine derivatives that are highly selective A2A/A2B inhibitors, the problems of insufficient selectivity and pharmacokinetics of existing adenosine A2A antagonists in the treatment of hyperproliferative and infectious diseases have been solved, achieving the effects of enhancing immune response and inhibiting immunosuppression.
Patent Information
- Application Number
- CN202080010474.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-01-22
- Filing Date
- 2020-01-21
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-01-21
AI Technical Summary
Existing adenosine A2A receptor antagonists have limitations in selectivity and pharmacokinetic properties when treating hyperproliferative and infectious diseases and disorders, and cannot effectively enhance immune responses or suppress immunosuppression.
A new class of thiazopyridine derivatives has been developed, which are highly effective inhibitors of A2A and A2B adenosine receptors, exhibiting high selectivity for A1 and A3 receptors and demonstrating better pharmacokinetic properties in mouse cancer models. They can rescue T cells from adenosine inhibition and enhance the immune response.
These compounds can effectively inhibit A2A and A2B receptors, reduce immunosuppression, support the activity of anti-tumor T cells, reduce tumor growth and metastasis, enhance the immune response to antigens, and provide better therapeutic effects.
Smart Images

Figure CN113939520B_ABST
Abstract
Description
[0001] The present invention relates to thiazolopyridine derivatives belonging to the general formula I,
[0002]
[0003] and the use of the compounds of the invention for treating and / or preventing hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions comprising such compounds. Background of the Invention
[0005] Adenosine is a ubiquitous regulator of a variety of physiological activities, particularly within the cardiovascular, nervous, and immune systems. Adenosine is structurally and metabolically related to the biologically active nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), and cyclic adenosine monophosphate (cAMP), to the biochemical methylating agent S-adenosyl-L-methionine (SAM), and to the coenzymes NAD, FAD, and coenzyme A, as well as to RNA.
[0006] Adenosine regulates a variety of physiological functions through cell surface receptors, including induction of sedation, vasodilation, inhibition of cardiac rhythm and contractility, inhibition of platelet aggregation, stimulation of gluconeogenesis, and inhibition of lipolysis. Studies have shown that adenosine can activate adenylate cyclase, open potassium channels, reduce flux through calcium channels, and inhibit or stimulate the turnover of phosphoinositide through receptor-mediated mechanisms (Muller CE and Stein B., Current Pharmaceutical Design, 2: 501, 1996; Muller CE, Exp. Opin. Ther. Patents, 7 (5): 419, 1997).
[0007] Adenosine receptors belong to the superfamily of G protein-coupled receptors (GPCRs). Four major subtypes of adenosine receptors have been characterized pharmacologically, structurally, and functionally (Fredholm et al., Pharm. Rev., 46:143-156, 1994), which are referred to as A 1 , A 2A , A 2B and A 3 Although the same adenosine receptor can be coupled to different G proteins, adenosine A 1 and A 3 The receptors are usually bound to inhibitory G proteins (called G i and G 0 ) coupled to the inhibitory G protein, which inhibits adenylate cyclase and downregulates cellular cAMP levels. 2A and A 2B G SThe stimulatory G protein couples to the stimulatory G protein, which activates adenylate cyclase and increases the intracellular cAMP level (Linden J., Annu. Rev. Pharmacol. Toxicol., 41: 775-87 2001).
[0008] According to the present invention, "adenosine receptor selective ligands" are substances that selectively bind to one or more subtypes of adenosine receptors, thereby mimicking the effects of adenosine (adenosine agonists) or blocking its effects (adenosine antagonists). Adenosine receptor selective ligands can be divided into different categories according to their receptor selectivity, such as Adenosine receptor selective ligands. 1 or A 2 The ligand that the receptor selectively binds, in the latter case, for example, to A 2A or A 2B Adenosine receptor ligands that selectively bind to multiple adenosine receptor subtypes are also possible, such as A 1 and A 2 The receptor selectively binds to A 3 The ligands to which the receptor selectively binds. The above receptor selectivity can be determined by the effect of the substance on a cell line that expresses the receptor subtype in question after stable transfection with the corresponding cDNA (Olah, ME et al., J. Biol. Chem., 267: 10764-10770, 1992). The effect of the substance on such a cell line can be monitored by biochemical determination of the intracellular messenger cAMP (Klotz, KN et al., Naunyn Schmiedebergs Arch. Pharmacol. 357: 1-9, 1998).
[0009] Known A 1 The receptor system involves activation of phospholipase C and regulation of both potassium and calcium channels. In addition to associating with adenylate cyclase, A 3 The isoform also stimulates phospholipase C, thereby activating calcium ion channels.
[0010] A cloned from various species (canine, human, rat, dog, chicken, cow, guinea pig) 1 Receptor (326-328 amino acids) with 90-95% sequence identity among mammalian species. A was cloned from dog, rat, human, guinea pig and mouse 2A Receptor (409-412 amino acids). Clone A from human and mouse 2B Receptor (332 amino acids), human A 2B With person A 1 and A 2A The receptor has 45% homology. A was cloned from human, rat, dog, rabbit and sheep 3Receptor (317-320 amino acids).
[0011] Someone suggested A 1 and A 2A The receptor subtypes play complementary roles in the regulation of energy supply by adenosine. Adenosine, a metabolite of ATP, diffuses from the cell and acts locally to activate adenosine receptors to reduce oxygen demand (A 1 and A 3 ), or increase oxygen supply (A 2A ), thereby restoring the balance of energy supply / demand within the tissue. Both isoforms act to increase the amount of oxygen available to the tissue and protect cells from damage caused by short-term oxygen imbalance. One of the important functions of endogenous adenosine is to prevent damage during trauma such as hypoxia, ischemia, hypotension, and epileptic seizures. In addition, adenosine receptor agonists are known to interact with rats expressing A 3 Mast cell binding of the receptor results in an increase in inositol triphosphate and intracellular calcium concentrations, which enhances antigen-induced secretion of inflammatory mediators. 3 The receptor plays a role in mediating asthma attacks and other allergic reactions.
[0012] These adenosine receptors are encoded by different genes and are classified according to their affinity for adenosine analogs and methylxanthine antagonists (Klinger et al., Cell Signal., 14(2):99-108, 2002).
[0013] The effects of adenosine on the nervous system were first observed with the most widely used of all psychotropic drugs, caffeine. In fact, caffeine is a well-known adenosine receptor antagonist that can enhance consciousness and learning in mammals. 2A The receptor pathway is responsible for these effects (Fredholm et al., Pharmacol. Rev., 51(1):83-133, 1999; Huang et al., Nat Neurosci., 8(7):858-9, 2005), and caffeine has an important effect on adenosine A 2A The action of receptor signaling pathways stimulates the highly specific and effective adenosine A 2A Antagonist research.
[0014] In mammals, adenosine A 2A The receptor has a limited distribution in the brain and is found in the striatum, olfactory tubercle, and nucleus accumbens (Dixon et al., Br. J. Pharmacol., 118(6):1461-8, 1996). High and moderate levels of expression can be observed in immune cells, heart, lungs, and blood vessels. In the peripheral system, G 3 Adenosine A 2AThe major G protein associated with the receptor, but in the striatum, striatal adenosine A 2A G o If the G protein to mediate its action (Kull et al., MoI.Pharmacol., 58 (4): 772-7, 2000), G o if and G 3 Similar to thymidine, and also couples to adenylate cyclase.
[0015] To date, studies on genetically modified mice and pharmacological analysis have shown that leukemia-associated peptides are not only useful for the treatment of central nervous system (CNS) disorders and diseases, such as Parkinson's disease, Huntington's disease, attention deficit hyperactivity disorder (ADHD), stroke (ischemic brain injury) and Alzheimer's disease (Fredholm et al., Annu. Rev. Pharmacol. Toxicol., 45:385-412, 2005; Higgins et al.; Behav. Brain Res. 185:32-42, 2007; DaIl'Igna et al., Exp. Neurol., 203(1):241-5, 2007; Arendash et al., Neuroscience, 142(4):941-52, 2006; Trends in Neurosci., 29(11), 647-654, 2006; Expert Opinion Ther. Patents, 17, 979-991, 2007; Exp. Neurol., 184(1), 285-284, 2003; Prog. Brain Res, 183, 183-208, 2010; J. Alzheimer Dis., Suppl 1, 117-126, 2010; J. Neurosci., 29(47), 14741-14751, 2009; Neuroscience, 166(2), 590-603, 2010; J. Pharmacol. Exp. Ther., 330(1), 294-303, 2009; Frontiers Biosci., 13, 2614-2632, 2008), and for the treatment of various organic causes of mental illness (Weiss et al., Neurology, 61(11 Suppl6):88-93,2003), A 2A Receptors are promising therapeutic targets.
[0016] Adenosine A 2A The use of receptor knockout mice has shown that adenosine A 2AReceptor inactivation prevents neuronal cell death caused by ischemia (Chen et al., J. Neurosci., 19(21):9192-200, 1999 and Monopoli et al., Neuroreport, 9(17):3955-9, 1998) and mitochondrial toxin 3-NP (Blum et al., J. Neurosci., 23(12):5361-9, 2003). 2A Antagonists provide a basis for the treatment of ischemia and Huntington's disease. 2A Blockade of the receptor also has an antidepressant effect (El Yacoubi et al., Neuropharmacology, 40(3):424-32, 2001). Finally, this blockade prevents memory dysfunction (Cunha et al., Exp. Neurol., 210(2):776-81, 2008; Takahashi et al., Front. Biosci., 13:2614-32, 2008), and this may be a promising therapeutic approach for the treatment and / or prevention of Alzheimer's disease.
[0017] About A 2A For reviews of adenosine receptors, see, e.g., Moreau et al. (Brain Res. Reviews 31:65-82, 1999) and Svenningsson et al. (Progress in Neurobiology 59:355-396, 1999).
[0018] To date, several adenosine A 2A Receptor antagonists have shown promising potential for treating Parkinson's disease. For example, KW-6002 (Istradefylline) completed a Phase III clinical trial in the United States after demonstrating its efficacy in alleviating disease symptoms (Bara-Himenez et al., Neurology, 61 (3): 293-6, 2003 and Hauser et al., Neurology, 61 (3): 297-303, 2003). SCH420814 (Preladenant) has been currently undergoing Phase II clinical trials in the United States and has produced improvements in motor function in animal models of Parkinson's disease (Neustadt et al., Bioorg. Med. Chem. Lett., 17 (5): 1376-80, 2001) and human patients (Hunter JC, poster Boston 2006-http: / / www.a2apd.org / Speakerabstracts / Hunter.pdf).
[0019] In addition to A2A In addition to the welcome utility of agonists of these receptors for the treatment of neurodegenerative diseases, these compounds have also been considered for complementary symptomatic indications. These are based on the following evidence: 2A Receptor activation may contribute to the pathophysiology of a range of neuropsychiatric disorders and functional disorders, such as depression, excessive daytime sleepiness, restless legs syndrome, attention deficit hyperactivity disorder and cognitive fatigue (Neurology, 61 (Suppl 6), 82-87, 2003; Behav. Pharmacol., 20(2), 134-145, 2009; CNS Drug Discov., 2(1), 1-21, 2007).
[0020] Some authors suggest that A 2A Antagonists are used to treat diabetes (WO1999035147; WO2001002400). Other studies have shown that A 2A Adenosine receptors are involved in wound healing and atrial fibrillation (Am. J. Path., 6, 1774-1778, 2007; Arthritis & Rheumatism, 54(8), 2632-2642, 2006).
[0021] Some of the effective adenosine A 2A Antagonists have entered clinical trials, showing positive effects and demonstrating the potential of this class of compounds not only for the treatment of neurodegenerative diseases such as Parkinson's disease, Huntington's disease or Alzheimer's disease, but also for other CNS-related diseases, such as depression, restless syndrome, sleep and anxiety disorders (Clin. Neuropharmacol., 33, 55-60, 2010; J. Neurosci., 30(48), 2010), 16284-16292; Parkinson Relat. Disord., 16(6), 423-426, 2010; Expert Opinion Ther. Patents, 20(8), 987-1005, 2010; Current Opinion in Drug Discovery & Development, 13(4), 466-480, 2010 and references therein; Mov. Disorders, 25(2), S305, 2010).
[0022] Known A 2AThe inhibitors are Istradefylline (KW-6002), Preladenant (SCH420814), SCH58261, CGS15943, Tozadenant, Vipadenant (V-2006), V-81444 (CPI-444, HTL-1071, PBF-509, Medi-9447, PNQ-370, ZM-241385, ASO-5854, ST-1535, ST-4206, DT1133 and DT-0926, which are in most cases developed for Parkinson's disease.
[0023] Adenosine A was cloned from rat hypothalamus (Rivkees and Reppert, 1992), human hippocampus (Pierce et al., 1992), and mouse mast cells (Marquardt et al., 1994) using standard polymerase chain reaction techniques and using degenerate oligonucleotide primers designed to recognize conserved regions of most G protein-coupled receptors. 2B Receptor. Human A 2B Receptor and rat and mouse A 2B The receptor shares 86 to 87% amino acid sequence homology with human A 1 and A 2A The receptors share 45% amino acid sequence homology. As expected for closely related species, the A 2B The receptors share 96% amino acid sequence homology. In contrast, A from different species 1 The overall amino acid identity shared between the receptors is 87% (Palmer and Stiles, 1995). 2A The receptors share 90% homology between species (Ongini and Fredholm, 1996), with most differences occurring in the second extracellular loop and the long C-terminal domain (Palmer and Stiles, 1995). 3 For receptor sequences, the lowest degree of identity between species was observed (72%) (Palmer and Stiles, 1995).
[0024] The adenosine analog NECA remains the most effective A 2B Agonists (Bruns, 1981; Feoktistov and Biaggioni, 1993, 1997; Brackett and Daly, 1994) are those that produce a half-maximal effect on adenylate cyclase stimulation (EC 50) is about 2 μM. However, it is non-selective and is expressed in low nanomolar (A 1 and A 2A ) or high nanomolar (A 3 ) within the range of EC 50 Activates other adenosine receptors with even greater affinity. 2B Characterization of receptors often relies on the lack of efficacy of compounds that are potent and selective agonists of other receptor types. 2B Receptors have been characterized by the process of elimination, i.e., by the lack of efficacy of agonists specific for other receptors. 2A The selective agonist CGS-21680 (Webb et al., 1992) can be used to distinguish A 2A Adenosine receptors and A 2B Adenosine receptors (Hide et al., 1992; Chern et al., 1993; Feoktistov and Biaggioni, 1995; van der Ploeg et al., 1996). Both receptors are positively coupled to adenylate cyclase and are activated by the non-selective agonist NECA. CGS-21680 is actually effective against A 2B The receptor is inactive but activates A 2A The receptor was as effective as NECA, with EC values of 1. 50 All are in the low nanomolar range (Jarvis et al., 1989; Nakane and Chiba, 1990; Webb et al., 1992; Hide et al., 1992; Feoktistov and Biaggioni, 1993; Alexander et al., 1996). 2B Receptor pair A 1 The selective agonist R-PIA (Feoktistov and Biaggioni, 1993; Brackett and Daly, 1994) and the 3 Selective agonist N 6 -(3-iodobenzyl)-N-methyl-5′-carbamoyladenosine (IB-MECA) (Feoktistov and Biaggioni, 1997) also has a low affinity. 2B Mediated cAMP accumulation, the distribution of agonists in human erythroleukemia (HEL) cells was determined to be NECA>R-PIA=IB-MECA>CGS-21680. The EC values of NECA and other agonists were 50 The difference between the two is about 2 orders of magnitude. Therefore, it is not R-PIA, IB-MECA, or CGS-21680 that elicits the response induced by NECA at concentrations in the low micromolar range (1–10 μM) that is responsible for the A 2B Receptor characteristics.
[0025] Although compared with other receptor subtypes, A 2B Receptors generally have a low affinity for agonists, but not for antagonists. 2B The structure-activity relationship of the receptor has not been fully characterized, but at least some xanthines are as potent as or more potent than other isoforms. 2B Antagonists of receptor subtypes. Specifically, DPSPX (1,3-dipropyl-8-sulfophenylxanthine), DPCPX (1,3-dipropyl-8-cyclopentylxanthine), DPX (1,3 diethylphenylxanthine), the antiasthmatic enprophylline (3-n-propylxanthine), and the non-xanthine compound 2,4-dioxobenzopteridine (alloxathine) have affinities in the mid to high nM range.
[0026] Other known A 2B The inhibitors are ATL801, PSB-605, PSB-1115, ISAM-140, GS6201, MRS1706 and MRS1754.
[0027] It is disclosed herein that adenosine receptors play a non-redundant role in down-regulating inflammation in vivo by acting as a physiological "STOP" (a termination mechanism) that can limit the immune response and thereby protect normal tissues from excessive immune damage during the pathogenesis of different diseases.
[0028] A 2A Receptor antagonists can enhance long-term immune responses by reducing T cell-mediated tolerance to antigenic stimulation, enhancing the induction of memory T cells, and improving the efficacy of passive antibody administration in the treatment of cancer and infectious diseases. 2A Receptor agonists can reduce the immune response in the long term by enhancing T cell-mediated tolerance to antigenic stimulation, particularly reducing the need for immunosuppressive agents under certain conditions.
[0029] Immunomodulation is a key aspect of the treatment of many diseases and disorders. T cells play a vital role in particular in resisting infection and have the ability to recognize and destroy cancer cells. Enhancing T cell-mediated responses is a key component in enhancing responses to therapeutic agents. However, it is crucial in immunomodulation that any enhancement of the immune response must be balanced with the need to prevent autoimmunity and chronic inflammation. Chronic inflammation and self-recognition by T cells are the main causes of the pathogenesis of systemic diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. In addition, in order to prevent the rejection of transplanted organs or grafts, long-term immunosuppression is required.
[0030] Tumor-induced immunosuppression is a major barrier to the efficacy of current cancer treatments. Recent successes with immune checkpoint blockade inhibitors (e.g., anti-CTLA-4 and anti-PD-1 / PDL1) are revolutionizing cancer treatment due to their remarkable clinical efficacy against a wide range of cancers.
[0031] Adenosine is one of the new promising immunosuppressive targets shown in preclinical studies. This metabolite is produced by the exoenzyme CD73 expressed on host suppressor cells and tumor cells. Increased expression of CD73 is associated with poor prognosis in patients with many cancers, including colorectal cancer (Liu et al., J. Surgical Oncol, 2012), gastric cancer (Lu et al., World J. Gastroenterol., 2013), and gallbladder cancer (Xiong et al., Cell and Tissue Res., 2014). Preclinical studies have shown that adenosine-mediated immunosuppression can (at least in part) drive the tumor-promoting effects of CD73. As disclosed above, adenosine binds to four known receptors A 1 , A 2A , A 2B and A 3 Combined, and known A 2A and A 2B Activation of the receptor inhibits the effector functions of many immune cells, namely A 2A and A 2B The receptor induces adenylate cyclase-dependent accumulation of cAMP, leading to immunosuppression. 1 and A 3 will counteract the desired effect, and A 1 and A 3 Agonists act as potential cardioprotective agents, therefore, it is necessary to achieve 1 and A 3 In the tumor microenvironment, it has been shown that A 2A and A 2B Activation of the A receptor inhibits antitumor immunity and increases the spread of CD73 tumors. 2A or A 2B It has been found that blocking A 2A The receptor can overcome tumor escape mechanisms, including anergy induced by tumor cells and regulatory T cell induction, and induce long-term tumor sensitivity to treatment. Ohta et al. demonstrated that compared with no rejection in normal mice, 2AIn mice deficient in the A receptor, approximately 60% of established CL8-1 melanoma tumors were rejected (Ohta, et al.; PNAS 103(35):13132-7, 2006). 2A Following receptor antagonist treatment, improved inhibition of tumor growth, disruption of metastasis, and prevention of neovascularization were achieved using anti-tumor T cells.
[0032] It has been shown that tumors evade immune destruction by preventing T cell activation by suppressing B7-CD28 and co-stimulatory factors in the TNF family and attracting regulatory T cells (which inhibit anti-tumor T cell responses) (Wang, Cancer. Semin. Cancer. Biol. 16:73-79, 2006; Greenwald, et al., Ann. Rev. Immunol. 23:515-48, 2005; Watts, Ann. Rev. Immunol. 23:23-68, 2005; Sadum et al., Clin. Cane. Res. 13(13):4016-4025, 2007). 2A Therefore, therapies that unleash lymphocyte effector responses (such as anti-CTLA-4 and anti-PD-1) may also enhance A 2A Mediated immunosuppression. 2A Antagonist or Double A 2A / 2B Immune checkpoint blockade with antagonists improves the extent of immune response to tumors and metastases. 2A Combination of inhibitory and anti-PD-1 therapy improves IFN-γ production by T cells, increases mouse survival in the 4T1 breast tumor model, and reduces AT-3ova dim CD73 + Tumor growth of tumors (Beavis et al., Cancer Immunol. Res., 2015; Mittal et al., Cancer Res., 2014).
[0033] In addition, preclinical studies have shown that A 2B Inhibition caused reduced tumor growth and prolonged survival in mice in Lewis lung cancer, MB49 bladder cancer, and orthotopic 4T1 breast cancer models (Ryzhov et al., 2009, Cekic et al., 2012), A 2B Combination inhibition with anti-PD-1 therapy reduced lung metastasis of B16-F10 melanoma tumors and improved mouse survival in the 4T1 breast tumor model.
[0034] WO 03 / 050241 describes methods for increasing the immune response to an antigen, increasing vaccine efficacy, or increasing the immune response to a tumor antigen or immune cell-mediated tumor destruction by administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors.
[0035] WO 2004 / 089942, WO 2005 / 000842 and WO 2006 / 008041 disclose A 2A WO 2004 / 092171 and WO 2005 / 028484 disclose similar thiazolopyridine and pyrazolopyrimidine derivatives, also as A 2A Inhibitors are used to treat Parkinson's disease. However, these compounds did not show significant A inhibition in rats (an animal model of Parkinson's disease). 2B In addition, these compounds have not shown that they can prevent immunosuppression and thus support the inhibition of tumor growth induced by anti-tumor T cells, the reduction or destruction of metastasis, and the prevention of new blood vessel formation.
[0036] Therefore, there is still a need for therapies that enhance the immune response to specific antigens in the long term, especially for the treatment and prevention of hyperproliferative and infectious diseases and disorders, and therefore, it is an object of the present invention to provide therapeutic methods that allow for the simplification of treatment regimens and enhance the immune response to certain antigens. A specific object of the present invention is to provide improved methods for preventing or treating hyperproliferative and infectious diseases and disorders in a host, and in particular to provide effective A for the treatment and prevention of such diseases. 2A Antagonist or Double A 2A / 2B Antagonist. SUMMARY OF THE INVENTION
[0038] It has been surprisingly found that the compounds of the present invention are A 2A Adenosine receptor or A 2A Adenosine receptors and A 2B Adenosine receptor inhibitor with high potency over A 1 Adenosine receptors and A 3 Due to their high selectivity for adenosine receptors, the compounds of the present invention are useful in the treatment of hyperproliferative diseases and disorders (eg, cancer) and infectious diseases and disorders.
[0039] Specifically, compared with the known adenosine A 2A Receptor antagonist Tozadenant and similar benzothiazole derivatives are very different, and the compounds of the present invention surprisingly show A 2A / A 2BDual activity, which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above; or the compounds of the present invention show at least a high A 2A The inhibitory activity, together with the other surprising advantages disclosed herein, results in high efficacy in the treatment and / or prevention of hyperproliferative and infectious diseases and disorders.
[0040] In addition, the known adenosine A 2A Compared to the receptor antagonist Tozadenant and similar benzothiazole derivatives, the compounds of the present invention surprisingly show better pharmacokinetic properties in mice as an animal model associated with cancer, which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above.
[0041] In addition, as discussed above, adenosine in the tumor microenvironment can be expressed via A 2A A suppresses T cell activity by inhibiting the signaling of the receptor and suppresses the secretion of cytokines by T cells. 2A Specific agonists, such as CGS-21680 or NECA, inhibit T cell cytokine secretion in vitro and in vivo, similar to adenosine. 2A Antagonist or A 2A / A2B Dual antagonists rescue T cells from this suppression. 2A The compounds of the present invention show that they can rescue T cells from suppression and prevent the inhibition of T cells by adenosine or A 2A Inhibition of cytokine secretion induced by specific agonists (e.g., CGS-2168, CGS-21680 or NECA), which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above. Thus, the compounds of the present invention are surprisingly able to prevent immunosuppression and thus are able to support the inhibition of tumor growth induced by anti-tumor T cells, the reduction or destruction of metastasis and the prevention of neovascularization.
[0042] The present invention relates to compounds selected from the group consisting of:
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055] and physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers thereof, including mixtures thereof in all ratios.
[0056] The compounds of the present invention belong to the general formula I,
[0057]
[0058] in
[0059] R 1 is a straight or branched alkyl group having 1 to 10 carbon atoms, which is unsubstituted or substituted by R 5 mono-, di- or tri-substituted, and 1 to 4 carbon atoms may be independently substituted by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –NR 6 SO 2 R 7 –, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3 -, -C≡C- groups and / or -CH=CH- groups, and / or in addition, 1 to 10 hydrogen atoms may be replaced by F and / or Cl; or a mono- or bicyclic cyclic alkyl group having 3 to 7 carbon atoms, which is unsubstituted or replaced by R 5 Mono-, di- or tri-substituted, wherein 1 to 4 carbon atoms may be independently substituted by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –NR 6 SO 2 R 7 –, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3-, -C≡C- groups and / or replaced by -CH=CH- groups, and / or in addition, 1 to 10 hydrogen atoms may be replaced by F and / or Cl; or a mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl group containing 3 to 14 carbon atoms and 0 to 4 heteroatoms independently selected from N, O and S, which group is unsubstituted or replaced by R 5 mono-, di- or tri-substituted,
[0060] R 2 is a straight or branched alkyl group having 1 to 10 carbon atoms, which is unsubstituted or substituted by R 5 mono-, di- or tri-substituted, and 1 to 4 carbon atoms may be independently substituted by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –NR 6 SO 2 R 7 –, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3 -, -C≡C- groups and / or -CH=CH- groups, and / or in addition, 1 to 10 hydrogen atoms may be replaced by F and / or Cl; or a cyclic alkyl group having 3 to 7 carbon atoms, which is unsubstituted or replaced by R 5 mono-, di- or tri-substituted, and 1 to 4 carbon atoms may be independently substituted by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –NR 6 SO 2 R 7 –, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3 -, -C≡C- groups and / or replaced by -CH=CH- groups, and / or in addition, 1 to 11 hydrogen atoms may be replaced by F and / or Cl; or a mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl group containing 3 to 14 carbon atoms and 0 to 4 heteroatoms independently selected from N, O and S, which group is unsubstituted or replaced by R 5 mono-, di- or tri-substituted,
[0061] R 3 is a straight or branched alkyl group having 1 to 6 carbon atoms or an O-alkyl group or a cyclic alkyl group having 3 to 6 carbon atoms, which is unsubstituted or substituted by H, =S, =NH, =O, OH, a cyclic alkyl group having 3 to 6 carbon atoms, COOH, Hal, NH 2 、SO 2 CH 3 、SO 2NH 2 、CN、CONH 2 NHCOCH 3 NHCONH 2 or NO 2 mono-, di- or tri-substituted,
[0062] R 4 is H, D, a straight or branched alkyl group having 1 to 6 carbon atoms, CN or Hal,
[0063] R 5 H, R 6 , =S, =NR 6 ,=O,OH,COOH,Hal,NH 2 、SO 2 CH 3 、SO 2 NH 2 、CN、CONH 2 NHCOCH 3 NHCONH 2 、NO 2 ; or a straight or branched alkyl group having 1 to 10 carbon atoms, which is unsubstituted or substituted by R 6 mono-, di- or tri-substituted, and 1 to 4 carbon atoms may be independently substituted by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –NR 6 SO 2 R 7 –, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3 -, -C≡C- groups and / or -CH=CH- groups, and / or in addition, 1 to 10 hydrogen atoms may be replaced by F and / or Cl; or a mono- or bicyclic cyclic alkyl group having 3 to 7 carbon atoms, which is unsubstituted or replaced by R 6 Mono-, di- or tri-substituted, wherein 1 to 4 carbon atoms may be independently substituted by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –NR 6 SO 2 R 7 –, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3-, -C≡C- groups and / or replaced by -CH=CH- groups, and / or in addition, 1 to 10 hydrogen atoms may be replaced by F and / or Cl; or a mono- or bicyclic heteroaryl, heterocyclyl, aryl or cyclic alkylaryl group containing 3 to 14 carbon atoms and 0 to 4 heteroatoms independently selected from N, O and S, which group is unsubstituted or replaced by R 6 mono-, di- or tri-substituted,
[0064] R 6 , R 7 independently selected from H, =S, =NH, =O, OH, COOH, Hal, NH 2 、SO 2 CH 3 、SO 2 NH 2 、CN、CONH 2 NHCOCH 3 NHCONH 2 、NO 2 and a straight or branched alkyl group having 1 to 10 carbon atoms, wherein 1 to 4 carbon atoms can be independently replaced by O, S, SO, SO 2 NH, NCH 3 , –OCO–, –NHCONH–, –NHCO–, –COO–, –CONH–, –NCH 3 CO–,–CONCH 3 -, -C≡C- groups and / or -CH=CH- groups, and / or in addition, 1 to 10 hydrogen atoms may be replaced by F and / or Cl,
[0065] Hal is F, Cl, Br or I.
[0066] D is deuterium,
[0067] and physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers thereof, including mixtures thereof in all ratios.
[0068] In addition, the following abbreviations have the following meanings:
[0069] Boc tert-Butyloxycarbonyl
[0070] CBZ benzyloxycarbonyl
[0071] DNP 2,4-Dinitrophenyl
[0072] FMOC 9-Fluorenylmethoxycarbonyl
[0073] imi-DNP 2,4-dinitrophenyl at the 1-position of the imidazole ring
[0074] OMe Methyl Ester
[0075] POA Phenoxyacetyl
[0076] DCCI Dicyclohexylcarbodiimide
[0077] HOBt 1-Hydroxybenzotriazole
[0078] The invention furthermore relates to pharmaceutical preparations comprising one of the compounds according to the invention and / or physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers thereof, including mixtures thereof in all ratios.
[0079] The present invention also relates to pharmaceutical preparations according to the invention of this type which comprise further excipients and / or adjuvants.
[0080] Furthermore, the present invention relates to the above pharmaceutical preparations according to the invention which comprise at least one further pharmaceutically active compound.
[0081] Pharmaceutically or physiologically acceptable derivatives are considered to refer to salts of compounds of the present invention, for example, and so-called prodrug compounds. Prodrug compounds are considered to refer to derivatives of compounds of the present invention that have been modified, for example, by alkyl or acyl groups (see also amino- and hydroxyl-protecting groups below), sugars or oligopeptides, and that rapidly break or release in the organism to generate effective molecules. These also include biodegradable polymer derivatives of compounds of the present invention, such as described in Int. J. Pharm. 115 (1995), 61-67.
[0082] The compounds of the present invention can be used in their final non-salt form. On the other hand, the present invention also includes the use of pepstatin in the form of its pharmaceutically acceptable salts, which can be obtained from various organic and inorganic bases by methods known in the art. Pharmaceutically acceptable salt forms of pepstatin are mostly prepared by conventional methods. If the compound of the present invention contains a carboxyl group, one of its suitable salts can be generated by reacting the compound of the present invention with a suitable base to obtain the corresponding base addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, such as potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. Aluminum salts of pepstatin are also included.
[0083] Additionally, base salts of the compounds of the present invention include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium, magnesium, manganese (III), manganese (II), potassium, sodium, and zinc salts, but this is not intended to be limiting.
[0084] Of the above salts, preferred are the ammonium; alkali metal sodium and potassium salts; and alkaline earth metal calcium and magnesium salts. Salts of the compounds of the invention derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines (also including naturally occurring substituted amines), cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucosamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a limitation.
[0085] As mentioned above, pharmaceutically acceptable base addition salts of pepstatin are formed with metals or amines (e.g., alkali metals and alkaline earth metals or organic amines). Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
[0086] Base addition salts of compounds of the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to cause the formation of the salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. In some aspects, the free acid form differs from its corresponding salt form with respect to certain physical properties, for example, solubility in polar solvents; however, for the purposes of the present invention, the salt is equivalent to its respective free acid form in other respects.
[0087] In view of the above, it can be seen that in this regard the term "pharmaceutically acceptable salt" should be taken to mean an active compound, including a compound of the invention, in the form of one of its salts, particularly where this salt form improves the pharmacokinetic properties of the active compound compared to the free form of the active compound or any other salt form of the active compound previously used. A pharmaceutically acceptable salt form of an active compound may also provide this active compound for the first time with desirable pharmacokinetic properties that it did not previously have, and may even have a positive effect on the pharmacodynamics of this active compound in terms of its efficacy in the body.
[0088] Solvates of the compounds according to the invention are taken to mean adducts of inert solvent molecules pepstatin which form owing to their mutual attractive forces. Solvates are, for example, hydrates, such as monohydrates or dihydrates, or alcoholates, ie addition compounds with alcohols, such as methanol or ethanol.
[0089] All physiologically acceptable salts, derivatives, solvates and stereoisomers of these compounds, including mixtures thereof in all ratios, also conform to the invention.
[0090] The compounds of the present invention may contain one or more chiral centers, and therefore, all stereoisomers, enantiomers, diastereomers, etc. of the compounds of the present invention are also claimed in the present invention.
[0091] The invention also relates to the optically active forms (stereoisomers), enantiomers, racemates, diastereomers and hydrates and solvates of these compounds.
[0092] The compounds of the present invention of the present invention can be chiral due to their molecular structure and therefore can exist in various enantiomeric forms. Therefore, they can be racemic or optically active forms. Since the drug efficacy of the racemate or stereoisomer of the compounds of the present invention may be different, it may be desirable to use enantiomers. In these cases, by chemical or physical methods known to those skilled in the art or which have been used in the synthesis, not only the final product but also the intermediate can be separated into enantiomeric compounds.
[0093] Pharmaceutically or physiologically acceptable derivatives are considered to mean, for example, salts of the compounds of the invention and so-called prodrug compounds. Prodrug compounds are considered to mean compounds of the invention which have been modified with, for example, alkyl or acyl groups (see also amino- and hydroxyl-protecting groups below), sugars or oligopeptides and which are rapidly broken or released in the organism to generate the active compounds of the invention. These also include biodegradable polymer derivatives of the compounds of the invention, as described, for example, in Int. J. Pharm. 115 (1995), 61-67.
[0094] Suitable acid addition salts are all inorganic or organic salts of physiologically or pharmacologically acceptable acids, for example halides (especially hydrochlorides or hydrobromides), lactates, sulfates, citrates, tartrates, maleates, fumarates, oxalates, acetates, phosphates, methanesulfonates or p-toluenesulfonates.
[0095] Very particular preference is given to the hydrochlorides, trifluoroacetates or bistrifluoroacetates of the compounds according to the invention.
[0096] Solvates of the compounds according to the invention are taken to mean adducts of inert solvent molecules onto the compounds according to the invention which are formed owing to their mutual attractive force. Solvates are, for example, hydrates, for example monohydrates or dihydrates, or alcoholates, i.e. addition compounds with alcohols, for example with methanol or ethanol.
[0097] The compounds of the invention are also intended to include isotopically labeled forms thereof. Isotopically labeled forms of the compounds of the invention are identical to such compounds except that one or more of the atoms of the compound has been replaced by an atom with an atomic mass or mass number different from the atomic mass or mass number of the atom normally found in nature. Examples of isotopes that are readily available and can be incorporated into the compounds of the invention by well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, for example, 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the invention, prodrugs or pharmaceutically acceptable salts thereof containing one or more of the above isotopes and / or other isotopes of other atoms are intended to be part of the invention. Isotopically labeled compounds of the invention can be used in a variety of advantageous ways. For example, compounds to which, for example, a radioactive isotope (e.g., 3 H or 14 C) of the present invention are suitable for drug and / or substrate tissue distribution assays. Due to the simplicity of preparation and excellent detectability, these radioactive isotopes (i.e., tritium ( 3 H) and carbon-14 ( 14 C)) is particularly preferred. Due to the higher metabolic stability of heavier isotope-labeled compounds, heavier isotopes (e.g. deuterium ( 2 H)) is combined with the compounds of the present invention has therapeutic advantages. Higher metabolic stability directly translates into extended half-life in vivo or lower dosage, which in most cases will represent a preferred embodiment of the present invention. In general, by carrying out the synthetic schemes and related instructions in the presented text, the procedures disclosed in the Examples section and the Preparation section of this article, the isotopically labeled compounds of the present invention can be prepared by replacing the non-isotopically labeled reactants with readily available isotopically labeled reactants.
[0098] In order to control the oxidative metabolism of compounds through the primary kinetic isotope effect, deuterium ( 2H) is incorporated into the compounds of the present invention. The primary kinetic isotope effect is caused by the exchange of isotopic nuclei, followed by a change in the rate of a chemical reaction caused by the change in the ground state energy required for covalent bond formation after such isotope exchange. The exchange of heavier isotopes generally causes a decrease in the ground state energy of a chemical bond, and thus results in a decrease in the rate of rate-limiting bond breakage. If bond breakage occurs in or near a saddle point region along the coordinates of a multi-product reaction, the product distribution ratio can be substantially changed. For example, if deuterium is bound to a carbon atom at a non-exchangeable position, then k M / k D = 2-7 rate differences are typical. If this rate difference is successfully used for a compound of the invention that is sensitive to oxidation, the in vivo distribution of the compound can thereby be significantly altered and the pharmacokinetic properties improved.
[0099] When discovering and developing therapeutic agents, those skilled in the art attempt to optimize pharmacokinetic parameters while maintaining desirable in vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic properties are susceptible to oxidative metabolism. Currently available in vitro liver microsomal assays provide valuable information about this type of oxidative metabolic process, which in turn allows for the rational design of deuterated compounds of the present invention that have improved stability by resisting this oxidative metabolism. The pharmacokinetic properties of the compounds of the present invention are thereby significantly improved, and can be improved in terms of in vivo half-life (T / 2), concentration at maximum therapeutic effect (C max ), expressed quantitatively in terms of increases in the area under the dose-response curve (AUC) and F, and reductions in clearance, dose, and raw material cost.
[0100] The following is intended to illustrate the above: The compounds of the present invention are prepared as a series of analogs, which have multiple potential attack sites for oxidative metabolism, for example, benzylic hydrogen atoms and hydrogen atoms bound to nitrogen atoms, in which various combinations of hydrogen atoms are replaced by deuterium atoms, so that some, most or all of these hydrogen atoms have been replaced by deuterium atoms. Half-life determinations can advantageously and accurately determine the extent of improved antioxidant metabolism. In this way, it is determined that the half-life of the parent compound can be extended by up to 100% due to this type of deuterium-hydrogen exchange.
[0101] In order to reduce or eliminate undesirable toxic metabolites, the metabolite profile of the starting compound can also be advantageously altered by replacing hydrogen with deuterium in the compounds of the invention. For example, if a toxic metabolite occurs by oxidative carbon-hydrogen (CH) bond cleavage, it is reasonable to assume that a deuterated analog will greatly reduce or eliminate the generation of the undesirable metabolite, even if the particular oxidation is not a rate-determining step. Further information on the state of the art for deuterium-hydrogen exchange is given, for example, in Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990, Reider et al., J. Org. Chem. 52, 3326-3334, 1987, Foster, Adv. Drug Res. 14, 1-40, 1985, Gillette et al., BioChemistry 33 (10) 2927-2937, 1994 and Jarman et al., Carcinogenesis 16 (4), 683-688, 1993.
[0102] The present invention also relates to mixtures of the compounds of the invention, for example, mixtures of two diastereomers in a ratio of 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000. These are particularly preferred mixtures of two stereoisomeric compounds. However, mixtures of two or more compounds of the invention are also preferred.
[0103] Furthermore, the invention relates to a process for preparing the compounds according to the invention, characterized in that
[0104] a) reducing a compound of formula II to obtain a compound of formula III, reacting the compound of formula III with a compound of formula IV at elevated temperature to obtain a compound of formula V, converting the compound of formula V to a compound of formula VI using a catalyst and a base, converting the compound of formula VI to a compound of formula VII by bromination, converting the compound of formula VII to a compound of formula VIII under substantially alkaline conditions, and reacting the compound of formula VIII with a compound of formula IX under standard amidation or urea formation conditions to obtain a compound of formula I,
[0105]
[0106] b) reacting a compound of formula V with a compound of formula X under Suzuki-type reaction conditions to obtain a compound of formula VI, converting the compound of formula VI to a compound of formula VII by bromination, converting the compound of formula VII to a compound of formula VIII under substantially basic conditions and reacting the compound of formula VIII with a compound of formula IX under standard amidation or urea formation conditions to obtain a compound of formula I,
[0107]
[0108] c) iodination of a compound of formula XII to obtain a compound of formula XIII, conversion of the compound of formula XIII to a compound of formula XIV by treatment with a base and an electrophilic reagent, conversion of the compound of formula XIV to a compound of formula XV by reduction, reaction of the compound of formula XV with a compound of formula IV at elevated temperature to obtain a compound of formula XVI, conversion of the compound of formula XVI to a compound of formula XVII under catalytic conditions, conversion of the compound of formula XVII to a compound of formula VIII under alkaline conditions, and reaction of the compound of formula VIII with a compound of formula IX under standard amidation or urea formation conditions to obtain a compound of formula I,
[0109]
[0110] d) a base of a compound of the invention is converted into one of its salts by treatment with an acid, or
[0111] e) Converting an acid of a compound of the present invention into one of its salts by treating it with a base.
[0112] It is also possible to carry out these reactions stepwise in each case and to vary the sequence of the linking reactions of the building blocks by modifying the concept of the protecting groups.
[0113] The starting materials or starting compounds are generally known. If they are novel, they can be prepared by methods known per se.
[0114] If desired, the starting materials can also be generated in situ by not isolating them from the reaction mixture but immediately converting them further into the compounds according to the invention.
[0115] Compound of the present invention is preferably obtained by releasing from their functional derivatives by solvolysis, specifically, by hydrolysis, or by hydrogenolysis. Preferred raw materials for solvolysis or hydrogenolysis are those comprising corresponding protected amino, carboxyl and / or hydroxyl groups instead of one or more free amino groups, carboxyl and / or hydroxyl groups, preferably those with amino protecting groups instead of the raw materials of the hydrogen atom connected with the nitrogen-atoms. In addition, preferably with the raw material of the hydrogen atom of the hydroxyl protecting group instead of the hydroxyl. Also preferably with the raw material of protected carboxyl instead of free carboxyl. Also multiple identical or different protected amino, carboxyl and / or hydroxyl groups may be present in the raw material molecule. If the protecting groups present are different from each other, then they can be selectively disconnected in many cases.
[0116] The term "amino protecting group" is generally known and relates to a group which is suitable for protecting (blocking) an amino group from chemical reactions, but which can be easily removed after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are in particular unsubstituted or substituted acyl groups, additionally unsubstituted or substituted aryl groups (e.g. 2,4-dinitrophenyl) or aralkyl groups (e.g. benzyl, 4-nitrobenzyl, triphenylmethyl). In addition, since the amino protecting groups are removed after the desired reaction or reaction sequence, their type and size are not critical, but preference is given to those having 1 to 20, in particular 1 to 8, carbon atoms. The term "acyl" is to be understood in the broadest sense in relation to the process of the invention. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkyloxycarbonyl. Examples of such acyl groups are alkanoyl groups, such as acetyl, propionyl, butyryl; aralkanoyl groups, such as phenylacetyl, arylformyl (e.g. benzoyl or toluoyl); aryloxyalkanoyl groups, such as phenoxyacetyl; alkoxycarbonyl groups, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; aralkyloxycarbonyl groups, such as CBZ, 4-methoxybenzyloxycarbonyl or FMOC. Preferred acyl groups are CBZ, FMOC, benzyl and acetyl.
[0117] The term "acid protecting group" or "carboxyl protecting group" is likewise generally known and relates to a group which is suitable for protecting a -COOH group against chemical reactions but which can be easily removed after the desired chemical reaction has been carried out elsewhere in the molecule. The free acid is usually replaced by an ester, for example a substituted and unsubstituted alkyl ester (e.g. methyl, ethyl, tert-butyl and substituted derivatives thereof), a substituted and unsubstituted benzyl ester or a silyl ester. The type and size of the acid protecting group are not critical, but preference is given to those having 1 to 20, in particular 1 to 10, carbon atoms.
[0118] The term "hydroxyl protecting group" is likewise generally known and relates to a group which is suitable for protecting a hydroxyl group from chemical reactions but which can be easily removed after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above-mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, in addition to alkyl groups. The type and size of the hydroxyl protecting group are not critical, but preferably those having 1 to 20, in particular 1 to 10, carbon atoms. Examples of hydroxyl protecting groups are especially benzyl, p-nitrobenzoyl, p-toluenesulfonyl and acetyl, of which benzyl and acetyl are preferred.
[0119] Further typical examples of amino-, acid- and hydroxyl-protecting groups are found, for example, in “Greene's Protective Groups in Organic Synthesis”, 4th edition, Wiley-Interscience, 2007.
[0120] The functional derivatives of the compounds according to the invention to be used as starting materials can be prepared by known methods of amino acid and peptide synthesis, as described, for example, in the said standard works and patent applications.
[0121] Depending on the protecting groups used, the compounds of the invention are released from their functional derivatives, for example with the aid of strong acids, advantageously trifluoroacetic acid or perchloric acid, but other strong mineral acids (e.g. hydrochloric acid or sulfuric acid), strong organic acids (e.g. trichloroacetic acid, or sulfonic acids (e.g. benzoylsulfonic acid or p-toluenesulfonic acid) may also be used. The presence of additional inert solvents and / or catalysts may be present, but is not always necessary.
[0122] According to the respective synthesis route, the starting materials can optionally be reacted in the presence of an inert solvent.
[0123] Suitable inert solvents are, for example, heptane, hexane, petroleum ether, DMSO, benzene, toluene, xylene, trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, for example methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, for example diethyl ether, isopropyl ether (preferably for substitution on the indole nitrogen), tetrahydrofuran (THF) or dioxane; glycol ethers, for example ethylene glycol monomethyl ether or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, for example acetone or butanone; amides, for example acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); nitriles, for example acetonitrile; esters, for example ethyl acetate; carboxylic acids or anhydrides, for example acetic acid or acetic anhydride; nitro compounds, for example nitromethane or nitrobenzene, optionally also mixtures of the solvents mentioned with one another or with water.
[0124] The amount of the solvent is not critical; preferably 10 g to 500 g of solvent may be added per g of the compound of the present invention to be reacted.
[0125] It may be advantageous to add acid binders, for example alkali metal or alkaline earth metal hydroxides, carbonates or bicarbonates or alkali metal or alkaline earth metal salts of other weak acids (preferably potassium, sodium or calcium salts), or organic bases, for example triethylamine, dimethylamine, pyridine or quinoline, or an excess of the amine component.
[0126] The obtained compounds of the present invention can be separated from the corresponding solutions in which they are prepared (e.g., by centrifugation and washing), and can be stored in another composition after separation, or they can be directly retained in the prepared solution. For specific uses, the obtained compounds of the present invention can also be absorbed in a desired solvent.
[0127] The reaction duration depends on the reaction conditions selected. Typically, the reaction duration is from 0.5 hour to 10 days, preferably from 1 to 24 hours. When using microwaves, the reaction time can be shortened to a value of from 1 to 60 minutes.
[0128] In addition, the compounds according to the invention and their preparation materials are prepared by known methods, as described in the literature (e.g., standard works such as Houben-Weyl, Methoden der organischen Chemie (Organic Chemistry Methods), Georg-Thieme-Verlag, Stuttgart), for example, under reaction conditions known and suitable for the reactions described. Variants known per se can also be used here, which are not described in more detail here.
[0129] Conventional work-up steps, such as addition of water to the reaction mixture and extraction, make it possible to obtain the compound after removal of the solvent. For further purification of the product, it may be advantageous to subsequently utilize distillation or crystallization or to carry out chromatographic purification.
[0130] The acids of the invention can be converted into the associated addition salts with a base, for example, by reacting equal amounts of the acid and base in an inert solvent such as ethanol, including evaporation. Suitable bases for this reaction are in particular those which give physiologically acceptable salts. Thus, the acids of the invention can be converted into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts with a base such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate. Organic bases which give physiologically acceptable salts, such as ethanolamine, are also suitable for this reaction.
[0131] On the other hand, available acid can make alkali of the present invention be converted into associated acid addition salt, for example, by making equal amount of alkali and acid react in inert solvent (such as ethanol), evaporate subsequently.The suitable acid for this reaction is particularly those acids that obtain physiologically acceptable salt.Therefore, inorganic acid can be used, for example sulfuric acid, nitric acid, hydrohalic acid (for example hydrochloric acid or hydrobromic acid), phosphoric acid (for example orthophosphoric acid), sulfamic acid, organic acid can be used in addition, particularly aliphatic, alicyclic, aromatic alicyclic, aromatic or heterocyclic, mono- or polycarboxylic acid, sulfonic acid or sulfuric acid, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, first or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxysulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene list and disulfonic acid or lauryl sulfuric acid. Salts with physiologically unacceptable acids, for example picrates, can be used to isolate and / or purify the compounds according to the invention.
[0132] It has been found that the compounds of the invention are well tolerated and have valuable pharmacological properties.
[0133] Because adenosine receptors (such as A 2A and A 2B ) have been shown to downregulate immune responses during inflammation and protect tissues from immune damage; therefore, inhibition of signaling through adenosine receptors could be used to enhance and prolong immune responses.
[0134] Provided herein is a method for improving immune response. In one example, the method increases desired and targeted tissue damage, such as damage to tumors (e.g., cancer). Disclosed herein is a method for inhibiting one or more processes that contribute to the production of extracellular adenosine and adenosine-triggered signaling through adenosine receptors. For example, immune response, local tissue inflammation, and targeted tissue destruction can be improved by: inhibiting or alleviating local tissue hypoxia that produces adenosine; degrading accumulated extracellular adenosine (or inactivating it); preventing or reducing the expression of adenosine receptors on immune cells; and / or inhibiting / antagonizing signaling by adenosine ligands through adenosine receptors. The results disclosed herein demonstrate that in subjects with various diseases (e.g., cancer and sepsis), tumors can be treated in vivo or immunity can be improved by in vivo administration of agents that destroy the "hypoxia->adenosine accumulation->immunosuppressive adenosine receptor signaling to immune cells" pathway.
[0135] In one example, the method includes administering one or more extracellular adenosine inhibitors and / or adenosine receptor inhibitors, such as adenosine receptor antagonists. To improve the efficacy of the vaccine, one or more adenosine receptor inhibitors and / or extracellular adenosine inhibitors can be administered in conjunction with the vaccine. In one example, one or more adenosine receptor inhibitors or extracellular adenosine inhibitors are administered to increase immune response / inflammation. In another example, a method is provided to achieve targeted tissue damage, such as for tumor destruction.
[0136] Therefore, the present invention also relates to the preparation of the compounds of the present invention for the treatment and / or prevention of 2A and / or A 2B Use of drugs for diseases caused, promoted and / or propagated by receptor agonists.
[0137] The present invention therefore also relates in particular to medicaments for the treatment and / or prevention of physiological and / or pathophysiological conditions, which medicaments comprise at least one of the compounds according to the invention and / or one of their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios.
[0138] Adenosine A 2A and / or A 2B Receptor-associated physiological and / or pathophysiological conditions.
[0139] Physiological and / or pathophysiological conditions are to be understood as referring to medically relevant physiological and / or pathophysiological conditions, such as diseases or illnesses and medical disorders, ailments, symptoms or complications etc., in particular diseases.
[0140] The invention also relates to a medicament for the treatment and / or prevention of physiological and / or pathophysiological conditions selected from hyperproliferative and infectious diseases and disorders, which medicament comprises at least one of the compounds according to the invention and / or one of their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios.
[0141] The invention also relates to a medicament for the treatment and / or prevention of physiological and / or pathophysiological conditions selected from hyperproliferative and infectious diseases and disorders, which medicament comprises at least one of the compounds according to the invention and / or one of their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, for use in the treatment and / or prevention of physiological and / or pathophysiological conditions selected from hyperproliferative and infectious diseases and disorders, wherein the hyperproliferative disease or disorder is cancer.
[0142] The present invention therefore particularly preferably relates to a medicament comprising at least one of the compounds according to the invention and / or one of their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, wherein the cancer is selected from acute and chronic lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, bladder cancer, brain cancer, breast cancer, cervical cancer, cervical hyperplasia, cervical cancer, choriocarcinoma, chronic myeloid leukemia, chronic lymphocytic leukemia, colon cancer, endometrial cancer, esophageal cancer, essential thrombocythemia, urogenital cancer, glioma, glioblastoma tumors, hairy cell leukemia, head and neck cancer, Hodgkin's disease, Kaposi's sarcoma, lung cancer, lymphoma, malignant carcinoid, malignant hypercalcemia, malignant melanoma, malignant pancreatic insulinoma, medullary thyroid cancer, melanoma, multiple myeloma, mycosis fungoides, myeloid and lymphocytic leukemia, neuroblastoma, non-Hodgkin's lymphoma, non-small cell lung cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, polycythemia vera, primary brain cancer, primary macroglobulinemia, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, skin cancer, small cell lung cancer, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, testicular cancer, thyroid cancer, and Wilms' tumor.
[0143] The present invention also preferably relates to a medicament for the treatment and / or prevention of physiological and / or pathophysiological conditions selected from hyperproliferative and infectious diseases and disorders, which medicament comprises at least one of the compounds according to the invention and / or one of their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, wherein the hyperproliferative disease or disorder is selected from age-related macular degeneration, Crohn's disease, liver cirrhosis, chronic inflammation-related disorders, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatous diseases, immune hyperproliferation associated with organ or tissue transplantation and immunoproliferative diseases or disorders selected from inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), vascular hyperproliferation secondary to retinal hypoxia and vasculitis.
[0144] The present invention also preferably relates to a medicament for the treatment and / or prevention of physiological and / or pathophysiological conditions selected from hyperproliferative and infectious diseases and disorders, which medicament comprises at least one of the compounds according to the invention and / or one of their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, wherein the infectious disease or disorder is selected from:
[0145] a) a virus-induced infectious disease caused by a retrovirus, a hepadnavirus, a herpesvirus, a Flaviviridae and / or an adenovirus, wherein the retrovirus is selected from a lentivirus or an oncorretrovirus, wherein the lentivirus is selected from HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV and EIAV, and the oncorretrovirus is selected from HTLV-I, HTLV-II and BLV, the hepadnavirus is selected from HBV, GSHV and WHV, the herpesvirus is selected from HSV I, HSV II, EBV, VZV, HCMV or HHV8, and the Flaviviridae is selected from HCV, West Nile virus and yellow fever virus,
[0146] b) bacterial infectious diseases caused by Gram-positive bacteria, wherein the Gram-positive bacteria are selected from methicillin-sensitive and methicillin-resistant Staphylococci (including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus and coagulase-negative Staphylococci), glycopeptide-intermediate-sensitive Staphylococcus aureus (GISA), penicillin-sensitive and penicillin-resistant Streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguinis and group C Streptococcus (GCS), group G Streptococcus (GGS) and viridans streptococci), enterococci (including vancomycin-sensitive and vancomycin-resistant strains such as Enterococcus faecalis and Enterococcus faecium), Clostridium difficile, Listeria monocytogenes, Corynebacterium jejuni, Chlamydia (including Chlamydia pneumoniae) and Mycobacterium tuberculosis,
[0147] c) bacterial infectious diseases caused by Gram-negative bacteria, wherein the Gram-negative bacteria are selected from the family Enterobacteriaceae, including Escherichia (including Escherichia coli), Klebsiella, Enterobacter, Citrobacter, Serratia, Proteus, Providencia, Salmonella, Shigella, Pseudomonas (including Pseudomonas aeruginosa), Moraxella (including Moraxella catarrhalis), Haemophilus and Neisseria,
[0148] d) infectious diseases caused by intracellular active parasites selected from the phylum Apicomplexa or Trichuris (including Trypanosoma, Plasmodium, Leishmania, Babesia or Theileria), Cryptosporidium, Sacrocystida, Amebas, Coccidia and Trichomonas.
[0149] The above disclosed medicaments are intended to include the corresponding use of the compounds of the present invention for the preparation of medicaments for the treatment and / or prevention of the above physiological and / or pathophysiological conditions.
[0150] Furthermore, the medicaments disclosed above are intended to include corresponding methods for the treatment and / or prevention of the above physiological and / or pathophysiological conditions, wherein at least one compound according to the invention is administered to a patient in need of such treatment.
[0151] As described in the examples, the compounds of the present invention preferably exhibit advantageous biological activities that can be readily demonstrated in enzyme assays and animal tests. In such enzyme-based assays, the compounds of the present invention preferably exhibit and cause an inhibitory effect, which is generally indicated by an IC in a suitable range. 50 The values are preferably in the micromolar range, more preferably in the nanomolar range.
[0152] The compounds of the invention can be administered to humans or animals, in particular mammals, such as apes, dogs, cats, rats or mice, and can be used for therapeutic treatment of the human or animal body and also for combating the above-mentioned diseases. They can also be used as diagnostic agents or reagents.
[0153] In addition, the compounds of the present invention can be used to separate adenosine A 2A and / or A 2B receptors and study their activity or expression. In addition, they are particularly suitable for interfering with adenosine A 2A and / or A 2B Therefore, the present invention also relates to the use of the compounds of the present invention for separating adenosine A 2A and / or A 2B Adenosine A receptors and the study of their activity or expression or their use 2A and / or A 2B Uses of receptor binders and inhibitors.
[0154] For diagnostic purposes, the compounds of the invention may, for example, be radiolabeled. Examples of radiolabeled 3 H. 14 C. 231 I and 125 I. The preferred labeling method is the indogen method (Fraker et al., 1978). In addition, the compounds of the present invention can be labeled by enzymes, fluorophores and chromophores. Examples of enzymes are alkaline phosphatase, β-galactosidase and glucose oxidase, examples of fluorophores are fluorescein, examples of chromophores are luminol, and for example, automatic detection systems for fluorescent staining are described in, for example, US 4,125,828 and US 4,207,554.
[0155] The present invention also relates to a pharmaceutical composition comprising the compound of the present invention and its use in the treatment and / or prevention of adenosine A 2A and / or A 2B Uses for diseases and disorders where partial or complete inactivation of the receptors may be beneficial.
[0156] The compounds of the present invention can be used for the preparation of pharmaceutical preparations, in particular by non-chemical methods. In this case, they are combined with at least one solid, liquid and / or semi-liquid excipient or adjuvant and optionally with one or more other active compounds to form a suitable dosage form.
[0157] Therefore, the present invention also relates to a pharmaceutical preparation comprising at least one compound of the present invention and / or its physiologically acceptable salts, derivatives, solvates and stereoisomers, including mixtures thereof in all proportions. Specifically, the present invention also relates to a pharmaceutical preparation comprising other excipients and / or adjuvants, and also to a pharmaceutical preparation comprising at least one other pharmaceutically active compound.
[0158] In particular, the present invention also relates to a process for the preparation of a pharmaceutical preparation, characterized in that a compound according to the invention and / or one of its physiologically acceptable salts, derivatives, solvates and stereoisomers, including mixtures thereof in all ratios, is brought into a suitable dosage form together with solid, liquid or semi-liquid excipients or adjuvants and optionally with other pharmaceutically active compounds.
[0159] The pharmaceutical preparations of the present invention can be used as drugs in human or veterinary medicine. The patient or host can belong to any mammalian species, such as primates, especially humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental studies, where they provide models for treating human diseases.
[0160] Suitable carrier materials are organic or inorganic substances, which are suitable for enteral (e.g. oral), parenteral or topical administration and do not react with the novel compound, such as water, vegetable oil (e.g. sunflower oil or cod liver oil), benzyl alcohol, polyethylene glycol, gelatin, carbohydrates (e.g. lactose or starch), magnesium stearate, talc, lanolin or vaseline. Due to professional knowledge, those skilled in the art are familiar with which adjuvant is suitable for the desired pharmaceutical preparation. In addition to solvents (e.g. water, physiological saline solution or alcohol (e.g. ethanol, propanol or glycerol), sugar solutions (e.g. glucose or mannitol solutions)) or mixtures of the solvents, gelling agents, tablet adjuvants and other active ingredient carriers, lubricants, stabilizers and / or wetting agents, emulsifiers, salts that affect osmotic pressure, antioxidants, dispersants, antifoaming agents, buffer substances, flavoring agents and / or spices or flavoring agents, preservatives, solubilizers or dyes may also be used. If desired, the preparation or medicine of the present invention may include one or more other active compounds, such as one or more vitamins.
[0161] If desired, the preparations or medicaments of the present invention may contain one or more other active compounds and / or one or more action enhancers (auxiliaries).
[0162] For the purposes of the present invention, the terms "pharmaceutical formulation" and "pharmaceutical preparation" are used synonymously.
[0163] As used herein, "pharmaceutically tolerable" refers to drugs, precipitating agents, excipients, adjuvants, stabilizers, solvents and other agents that facilitate administration of the drug formulations derived therefrom to mammals without undesirable physiological side effects such as nausea, dizziness, digestive problems, and the like.
[0164] In pharmaceutical preparations for parenteral administration, isotonicity, normal hydration and tolerability as well as safety of the preparation (low toxicity), the auxiliary agents used and the primary packaging are required. Surprisingly, the compounds of the present invention preferably have the advantage that they can be used directly, so that no further purification steps for removing toxicologically unacceptable agents (e.g. high concentrations of organic solvents or other toxicologically unacceptable auxiliary agents) are necessary before the compounds of the present invention are used in pharmaceutical formulations.
[0165] The present invention particularly preferably also relates to pharmaceutical preparations comprising at least one compound according to the invention in precipitated amorphous, precipitated crystalline or dissolved or suspended form and optionally excipients and / or adjuvants and / or other pharmaceutically active compounds.
[0166] The compounds according to the invention preferably allow the preparation of high-concentration formulations without disadvantageous, undesirable aggregation of the compounds according to the invention. Thus, ready-to-use solutions having a high active ingredient content can be prepared with the aid of the compounds according to the invention with aqueous solvents or in aqueous media.
[0167] These compounds and / or their physiologically acceptable salts and solvates can also be lyophilized, the resulting lyophilizates being used, for example, for the preparation of injection preparations.
[0168] Aqueous preparations can be prepared by dissolving or suspending the compound of the present invention in an aqueous solution and optionally adding an adjuvant. For this purpose, a defined volume of a stock solution containing the other adjuvants of a defined concentration is advantageously added to a solution or suspension having a defined concentration of the compound of the present invention, and the mixture is optionally diluted with water to a pre-calculated concentration. Alternatively, adjuvants can be added in solid form. Subsequently, a certain amount of stock solution and / or water necessary in each case can be added to the resulting aqueous solution or suspension. The compound of the present invention can also advantageously be directly dissolved or suspended in a solution containing all other adjuvants.
[0169] Solutions or suspensions containing the compounds of the invention having a pH of 4 to 10, preferably a pH of 5 to 9, and an osmotic mass of 250 to 350 mOsmol / kg can advantageously be prepared. Thus, the pharmaceutical preparations can be administered directly intravenously, intraarterially, intraarticularly, subcutaneously or transdermally substantially painlessly. In addition, the preparations can also be added to infusion solutions, such as glucose solutions, isotonic saline solutions or Ringer's solutions, which can also contain other active compounds, and thus relatively large amounts of active compounds can also be administered.
[0170] The pharmaceutical preparations according to the invention may also comprise a mixture of a plurality of compounds according to the invention.
[0171] The preparations of the invention are physiologically well tolerated, easy to prepare, accurately dispensed, and preferably stable in terms of assays, decomposition products and aggregates throughout storage and transport and during multiple freezing and thawing processes. They can preferably be stored in a stable manner at refrigerator temperature (2-8° C.) and room temperature (23-27° C.) and 60% relative atmospheric humidity (RH) for a period of at least three months to two years.
[0172] For example, the compounds of the present invention can be stored in a stable manner by drying and, if necessary, converted into ready-to-use pharmaceutical preparations by dissolving or suspending. Possible drying methods are, for example, but not limited to, the following examples: nitrogen drying, vacuum oven drying, freeze drying, washing with an organic solvent and then air drying, liquid bed drying, fluidized bed drying, spray drying, roller drying, layer drying, room temperature air drying, and other methods.
[0173] The term "effective amount" refers to that amount of a drug or pharmaceutically active compound that elicits the biological or medical response of a tissue, system, animal or human that is being sought or desired, for example, by a researcher or physician.
[0174] In addition, the term "therapeutically effective amount" refers to an amount that has the following results: improves treatment, cures, prevents or eliminates a disease, syndrome, disease condition, ailment, disorder or prevents side effects or also slows the development of a disease, ailment or disorder, compared to a corresponding subject not receiving such an amount. The term "therapeutically effective amount" also includes an amount that is effective to enhance normal physiological function.
[0175] When using the preparation or medicine of the present invention, the compound of the present invention and / or its physiologically acceptable salt and solvate are usually used similarly to known, commercially available preparations or preparations, preferably with a dosage between 0.1 and 500 mg per use unit, particularly between 5 and 300 mg. The daily dose is preferably between 0.001 and 250 mg / kg body weight, particularly between 0.01 and 100 mg / kg body weight. The preparation can be applied once or multiple times a day, for example, two, three or four times a day. However, the individual dosage of the patient depends on many individual factors, for example, depending on the efficacy, age, body weight, overall health, sex, nutrition, application time and method, excretion rate, combination with other drugs, and severity and duration of a specific disease of the specific compound used.
[0176] The measure of the absorption of a pharmaceutically active compound in an organism is its bioavailability. If a pharmaceutically active compound is delivered intravenously to an organism in the form of an injection solution, its absolute bioavailability, that is, the proportion of the drug that reaches the systemic blood, i.e., the main circulation, in an unchanged form, is 100%. In the case of oral administration of therapeutically active compounds, the active compound is usually in solid form in the preparation and must therefore first be dissolved so that it can overcome barriers to entry, such as the gastrointestinal tract, oral mucosa, nasal membranes or skin, particularly the stratum corneum, or can be absorbed by the body. Data on pharmacokinetics, i.e., bioavailability data, can be obtained similarly to the methods of J. Shaffer et al., J. Pharm. Sciences, 88 (1999), 313-318.
[0177] Otherwise, a medicament of this type can be prepared by one of the methods generally known in the pharmaceutical art.
[0178] The medicament may be adapted for administration by any desired suitable route, for example, by oral (including buccal or sublingual), rectal, pulmonary, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, especially intraarticular) routes. Medicaments of this type may be prepared by all methods known in the pharmaceutical art, for example, by combining the active compound with excipients or adjuvants.
[0179] Parenteral administration is preferably suitable for the administration of the medicament of the present invention. In the case of parenteral administration, intra-articular administration is particularly preferred.
[0180] Therefore, the present invention also preferably relates to the use of the pharmaceutical preparation according to the invention for intra-articular administration in the treatment and / or prevention of physiological and / or pathophysiological conditions selected from osteoarthritis, traumatic cartilage lesions, arthritis, pain, allodynia or hyperalgesia.
[0181] The advantage of intra-articular administration is that the compound of the present invention can be directly administered to the synovial fluid near the articular cartilage, and can also diffuse into the cartilage tissue from there. Therefore, the pharmaceutical preparation of the present invention can also be directly injected into the joint space, thereby directly exerting its effect at the expected site of action. The compound of the present invention is also suitable for preparing a drug with slow, continuous and / or controlled release of an active compound to be administered parenterally. Therefore, they are also suitable for preparing a sustained-release preparation, which is advantageous to the patient because it only needs to be administered at relatively long intervals.
[0182] Drugs adapted for parenteral administration include: aqueous and non-aqueous sterile injection solutions, which contain antioxidants, buffers, bacteriostats and solutes, thereby giving the preparation isotonicity with the blood or synovial fluid of the recipient to be treated; and aqueous and non-aqueous sterile suspensions that may contain suspending media and thickeners. The preparations can be delivered in single-dose or multi-dose containers, such as sealed ampoules and vials, and can be stored in a freeze-dried (lyophilized) state so that only a sterile carrier liquid, such as water for injection, needs to be added directly before use. Injection solutions and suspensions prepared according to the formula can be prepared from sterile powders, granules and tablets.
[0183] The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
[0184] The compound of the present invention can also be coupled to a soluble polymer as a targeted drug excipient. Such polymers can include polyvinyl pyrrolidone, pyran copolymers, polyhydroxypropyl methacrylamidophenol, polyhydroxyethyl aspartamide phenol or polyethylene oxide polylysine substituted by palmitoyl. The compound of the present invention can also be coupled to a class of biodegradable polymers suitable for realizing slow release of drugs, such as polylactic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, lactic acid-glycolic acid copolymers, polymers such as conjugates between dextran and methacrylate, polyphosphates, various polysaccharides and polyamines and poly-ε-caprolactone, albumin, chitosan, collagen or modified gelatin and crosslinked or amphiphilic block copolymers of hydrogels.
[0185] Suitable for enteral administration (oral or rectal) are in particular tablets, dragees, capsules, syrups, juices, drops or suppositories, suitable for topical use are ointments, creams, pastes, lotions, gels, sprays, foams, aerosols, solutions (for example in alcohols (such as ethanol or isopropanol), acetonitrile, DMF, dimethylacetamide, 1,2-propylene glycol or mixtures thereof with each other and / or with water) or powders. Liposomal preparations are also particularly suitable for topical use.
[0186] In the case of formulation to give an ointment, the active compounds may be formulated with either a paraffinic or a water-miscible cream base. Alternatively, the active compounds may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
[0187] Drugs adapted for transdermal administration may be delivered as a separate plaster which is placed in close and prolonged contact with the recipient's epidermis. Thus, for example, the active compound may be supplied from the plaster by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
[0188] Of course, in addition to the ingredients specifically mentioned above, the medicament of the present invention may also contain other agents commonly used in the art in connection with a particular type of pharmaceutical preparation.
[0189] The invention also relates to a kit consisting of the following individual packages:
[0190] a) an effective amount of a compound according to the invention and / or its physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios, and
[0191] b) an effective amount of another pharmaceutically active compound.
[0192] The kit includes suitable containers, such as boxes or cartons, individual bottles, bags or ampoules. The kit may, for example, include separate ampoules, each containing an effective amount of a compound of the invention and / or a pharmaceutically acceptable salt, derivative, solvate, prodrug and stereoisomer thereof (including mixtures thereof in all proportions) in dissolved or lyophilized form and an effective amount of other pharmaceutically active compounds.
[0193] Additionally, the medicaments of the present invention may be used to provide an additive or synergistic effect in certain known therapies, and / or may be used to restore the efficacy of certain existing therapies.
[0194] In addition to the compounds of the present invention, the pharmaceutical preparations of the present invention may also contain other pharmaceutically active compounds, for example other antitumor drugs for the treatment of cancer. In order to treat the other diseases mentioned, in addition to the compounds of the present invention, the pharmaceutical preparations of the present invention may also contain other pharmaceutically active compounds known to those skilled in the art in their treatment.
[0195] In a main embodiment, a method for enhancing the immune response of a host in need is provided. By reducing T cell tolerance, including by increasing IFN-γ release, by reducing regulatory T cell production or activation, or by increasing antigen-specific memory T cell production in the host, the immune response can be enhanced. In one embodiment, the method includes combining or alternating administration of the compound of the present invention to the host with an antibody. In a specific sub-embodiment, the antibody is a therapeutic antibody. In a specific embodiment, a method for enhancing the efficacy of passive antibody therapy is provided, the method including combining or alternating administration of the compound of the present invention with one or more passive antibodies. This method can improve the efficacy of antibody therapy for the treatment of abnormal cell proliferative disorders (such as cancer), or can improve the efficacy of therapy in the treatment or prevention of infectious diseases. The compound of the present invention can be combined or alternating administration with antibodies such as rituximab, Herceptin or Erbitux.
[0196] In another major embodiment, there is provided a method of treating or preventing abnormal cellular proliferation, the method comprising administering to a host in need thereof a compound of the present invention in the substantial absence of another anticancer agent.
[0197] In another major embodiment, a method of treating or preventing abnormal cell proliferation in a host in need thereof is provided, the method comprising first administering to the host a compound of the present invention in combination with a first anticancer agent, followed by administering a second A 2A and / or A 2B In one sub-embodiment, the second antagonist is administered substantially in the absence of another anticancer agent. In another major embodiment, a method of treating or preventing abnormal cell proliferation in a host in need thereof is provided, the method comprising administering a compound of the invention to the host substantially in combination with a first anticancer agent, followed by administration of the second anticancer agent in the absence of the antagonist.
[0198] Thus, the cancer treatment disclosed herein can be performed as a therapy utilizing the compounds of the present invention or in combination with surgery, irradiation or chemotherapy. This type of chemotherapy may include the use of one or more active compounds of the following anti-tumor active compound classes:
[0199] (i) antiproliferative / antitumor / DNA damaging active compounds and combinations thereof for use in medical oncology, such as alkylating active compounds (e.g. cisplatin, parboplatin, cyclophosphamide, mechlorethamine, melphalan, chlorambucil, busulfan and nitrosoureas); antimetabolites (e.g. antifolates, such as fluoropyrimidines, e.g. 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumor antibiotics (e.g. anthracyclines, such as doxorubicin, bleomycin, doxorubicin); compounds with antimitotic activity (e.g. vinca alkaloids, such as vincristine, vinblastine, vindesine and vinorelbine, and taxanes, such as paclitaxel and taxotere); topoisomerase inhibitors (e.g. epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, irinotecan and camptothecin) and cell differentiation active compounds (e.g. all-trans retinoic acid, 13-cis-retinoic acid and retinamide);
[0200] (ii) cytostatically active compounds, such as antiestrogens (e.g. tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), estrogen receptor modulators (e.g. fulvestrant), antiandrogens (e.g. bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (e.g. goserelin, leuprolide and buserelin), progestins (e.g. megestrol acetate), aromatase inhibitors (e.g. anastrozole, letrozole, vorozole and exemestane) and inhibitors of 5α-reductase (e.g. finasteride);
[0201] (iii) active compounds that inhibit cancer invasion, including, for example, metalloproteinase inhibitors (such as marimastat) and inhibitors of urokinase plasminogen activator receptor function;
[0202] (iv) inhibitors of growth factor function, such as growth factor antibodies, growth factor receptor antibodies, such as the anti-ErbB2 antibody trastuzumab [Herceptin TM] and the anti-erbbl antibody cetuximab [C225], farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine / threonate kinase inhibitors, such as inhibitors of the epidermal growth factor family (e.g. EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), inhibitors of the platelet-derived growth factor family, and inhibitors of the hepatocyte growth factor family, for example;
[0203] (v) anti-angiogenic active compounds, such as bevacizumab, angiostatin, endostatin, linomide, batimastat, captopril, cartilage-derived inhibitors, genistein, interleukin 12, lavandin, medroxyprogesterone acetate, recombinant human platelet factor 4, teicogalan, thrombospondin, TNP-470, anti-VEGF monoclonal antibodies, soluble VEGF receptor chimeric proteins, anti-VEGF receptor antibodies, anti-PDGF receptors, integrin inhibitors, tyrosine kinase inhibitors, serine / threonine kinase inhibitors, antisense oligonucleotides, antisense oligodeoxynucleotides, siRNAs, anti-VEGF aptamers, pigment epithelium-derived factors and compounds disclosed in international patent applications WO 97 / 22596, WO 97 / 30035, WO 97 / 32856 and WO 98 / 13354;
[0204] (vi) Vascular disrupting agents, such as Compretin A4 and compounds disclosed in International Patent Applications WO 99 / 02166, WO 00 / 40529, WO 00 / 41669, WO 01 / 92224, WO 02 / 04434 and WO 02 / 08213;
[0205] (vii) antisense therapies, such as those directed against the targets listed above, e.g., ISIS 2503, an anti-Ras antisense agent;
[0206] (viii) gene therapy approaches, including, for example, methods of replacing abnormal, modified genes (e.g., abnormal p53 or abnormal BRCA1 or BRCA2), GDEPT approaches (gene-directed enzyme prodrug therapy), such as those using cytosine deaminase, thymidine kinase or bacterial nitroreductase, and methods of improving a patient's tolerance to chemotherapy or radiation therapy, such as multidrug resistance therapy; and
[0207] (ix) immunotherapy methods, including, for example, ex vivo and in vivo methods for increasing the immunogenicity of a patient's tumor cells, such as transfection with cytokines such as interleukin 2, interleukin 4, or granulocyte macrophage colony stimulating factor, methods for reducing T cell anergy, methods using transfected immune cells such as cytokine-transfected dendritic cells, methods using cytokine-transfected tumor cells, and methods using anti-idiotypic antibodies;
[0208] (x) Chemotherapeutic agents, including, for example, abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretinoin, amifostine, anastrozole, arsenic trioxide, asparaginase, BCG live, bevacizumab, bexarotene, bleomycin, bortezomib, busulfan, carlotestosterone, camptothecin, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cinacalcet, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, actinomycin, darbepoetin alfa, daunorubicin, denileukin, dexrazoxane, docetaxel, doxorubicin, drostanolone, epirubicin, epoetin alfa, estramustine, etoposide, exemestane, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, and gemcitabine.
[0209] Drugs from Table 1 may preferably, but not exclusively, be combined with the compounds of the present invention.
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216] Even without further embodiments, it is envisaged that a person skilled in the art will be able to use the above description in the broadest scope. Therefore, the preferred embodiments should be considered only as a descriptive disclosure which is absolutely not limiting in any way.
[0217] Therefore, the following examples are intended to illustrate the invention without limiting it. Unless otherwise indicated, percentage data represent weight percentages. All temperatures are expressed in degrees Celsius. "Conventional work-up": If necessary, water is added, if necessary, the pH is adjusted to a value between 2 and 10 depending on the composition of the final product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulphate, filtered and evaporated, and the product is purified by chromatography on silica gel and / or by crystallization.
[0218] Rf value on silica gel; mass spectrum: EI (electron impact ionization): M + , FAB (Fast Atom Bombardment): (M+H) + , THF (tetrahydrofuran), NMP (N-methylpyrrolidone), DMSO (dimethyl sulfoxide), EA (ethyl acetate), MeOH (methanol), TLC (thin layer chromatography)
[0219] List of abbreviations
[0220] AUC Area under the plasma drug concentration-time curve
[0221] C max Maximum plasma concentration
[0222] CL clearance
[0223] CV Coefficient of variation
[0224] CYP Cytochrome P450
[0225] DMSO Dimethyl sulfoxide
[0226] F Bioavailability
[0227] f a Absorbed fraction
[0228] iv intravenous
[0229] LC-MS / MS Liquid chromatography tandem mass spectrometry
[0230] LLOQ Lower limit of quantitation
[0231] NC Not calculated
[0232] ND Not determined
[0233] PEG Polyethylene glycol
[0234] Pgp permeability glycoprotein
[0235] PK Pharmacokinetics
[0236] po Per os (oral)
[0237] t 1 / 2 half life
[0238] t max Time to reach maximum plasma drug concentration
[0239] UPLC Ultra-Performance Liquid Chromatography
[0240] V ss Distribution volume (at steady state)
[0241] v / v volume / volume
[0242] Example 1: Examples of compounds of the present invention
[0243] The invention relates in particular to the compounds of Table 2 and their physiologically acceptable salts, derivatives, solvates, prodrugs and stereoisomers, including mixtures thereof in all ratios.
[0244] Table 2 - Examples of compounds of the invention
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282] Table 3 - NMR spectra of compounds of the invention
[0283] The numbers stated here correspond to the compound numbers disclosed in Table 2.
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305] Example 2: Preparation and analysis of the compounds of the present invention
[0306] All solvents used were commercially available and used without further purification. Reactions were usually carried out under an inert atmosphere of nitrogen using anhydrous solvents. Flash column chromatography was usually carried out using silica gel 60 (0.035-0.070 mm particle size).
[0307] All NMR experiments were recorded at 400 MHz on a Bruker Mercury Plus 400 NMR spectrometer equipped with a Bruker 400 BBFO probe or at 300 MHz on a Bruker Mercury Plus 300 NMR spectrometer equipped with a Bruker 300 BBFO probe. All deuterated solvents typically contained 0.03% to 0.05% v / v tetramethylsilane, which was used as a reference signal (for 1 H and 13 C, both are set at δ = 0.00).
[0308] LC-MS analysis was performed on a SHIMADZU LC-MS machine consisting of a UFLC 20-AD system and a LCMS 2020 MS detector. The column used was Shimpack XR-ODS, 2.2 μm, 3.0x50 mm. A linear gradient was applied, starting from 95% A (A: 0.05% TFA / water) and ending at 100% B (B: 0.05% TFA / acetonitrile), over 2.2 minutes, with a total run time of 3.6 minutes. The column temperature was 40°C and the flow rate was 1.0 mL / min. The diode array detector was scanned from 200-400 nm. The mass spectrometer was equipped with an electrospray ion source (ES) operating in positive or negative mode. The mass spectrometer scanned between m / z90-900 with a scan time of 0.6 s. Unless otherwise stated.
[0309] 1. (5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 24
[0310] and (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 25
[0311]
[0312] a.4-Chloro-5-iodo-3-nitropyridine-2-ol
[0313] 4-Chloro-3-nitropyridine-2-ol (10.0 g, 54.4 mmol, 95%), N-iodo-succinimide (NIS, 14.2 g, 59.9 mmol, 95%) / acetonitrile (115 mL) were placed in a 250 mL round-bottom flask. The solution was stirred in an oil bath at 80 ° C for 1 hour overnight. The mixture was concentrated and the precipitate formed was collected by filtration. The residue was washed twice with petroleum ether (500 mL) and dried in vacuo at 60 ° C overnight. This gave 4-chloro-5-iodo-3-nitropyridine-2-ol (16.5 g, 97.9%, 97% purity) as a yellow solid. MS: m / z=300.9[M+H] + .
[0314] b.4-Chloro-5-iodo-2-methoxy-3-nitropyridine
[0315] In a 500 mL round-bottom flask, 4-chloro-5-iodo-3-nitropyridine-2-ol (16.5 g, 53.3 mmol, 97%), Ag 2 CO 3 (15.5 g, 53.3 mmol, 95%) / toluene (310 mL). CH 3 I (15.9 g, 107 mmol, 95%), and the mixture was stirred at 80 ° C for 4 hours. The precipitate was collected by filtration and discarded. The filtrate was evaporated to dryness in vacuo and the residue was purified by silica gel chromatography with ethyl acetate / petroleum ether (15:85). This gave 4-chloro-5-iodo-2-methoxy-3-nitropyridine (9.90 g, 52.6%, 89% purity) as a light yellow solid. MS: m / z = 315.5 [M+H] + .
[0316] c. 4-Chloro-5-iodo-2-methoxypyridin-3-amine
[0317] In a 250 mL three-necked round-bottom flask, 4-chloro-5-iodo-2-methoxy-3-nitropyridine (9.90 g, 28.0 mmol, 89%), iron (16.5 g, 281 mmol, 95%) and NH 4 Cl (9.40 g, 174 mmol, 99%) / ethanol (152 mL) and water (30 mL). The mixture was stirred at 80 ° C in an oil bath for 2 hours. The reaction mixture was filtered through diatomaceous earth, washed with ethanol and the mother liquor was concentrated to dryness. The residue was stirred for 30 minutes. 100 ml of water was dried in vacuo at 60 °. This gave 4-chloro-5-iodo-2-methoxypyridine-3-amine (7.20 g, 75%, 83% purity) as an off-white solid. It was used in the next step without further purification. MS: m / z = 285.9 [M + H] + .
[0318] dN-[7-iodo-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide
[0319] 4-Chloro-5-iodo-2-methoxypyridin-3-amine (7.20 g, 21.0 mmol, 83%) / acetone (150 mL) was placed in a 500 mL round-bottom flask, and benzoyl isothiocyanate (5.21 g, 31.5 mmol, 99%) was added dropwise at room temperature. The solution was stirred at 50 ° C for 1 hour in an oil bath. The solid was collected by filtration, washed with acetone and dried in vacuo to give N-[7-iodo-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (8.73 g, 91%, 90% purity) as a white solid. MS: m / z = 412.2 [M+H] + .
[0320] eN-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide
[0321] To a solution of N-[7-iodo-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (6.00 g, 13.1 mmol, 90%) and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6.13 g, 27.7 mmol, 95%) in dioxane (200 mL) and water (40.00 mL) was added NaOH (2.90 g, 68.9 mmol, 95%) and Pd(dppf)Cl 2 * Dichloromethane (1.20 g, 1.40 mmol, 95%). After stirring at 100 ° C. for 1 hour under a nitrogen atmosphere, the mixture was concentrated to dryness in vacuo. The residue was purified by silica gel chromatography with ethyl acetate / hexane (95:5). This gave 3.32 g (62%, 90% purity) of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide as a colorless solid. MS: m / z=368.1[M+H] + .
[0322] f. 7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-amine
[0323] To a stirred mixture of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (3.27 g, 8.00 mmol, 90%) in water / methanol (1:1, 300 mL) was added NaOH (3.36 g, 80.0 mmol, 95%) at room temperature under nitrogen atmosphere. The mixture was stirred at 90 °C overnight under nitrogen atmosphere and evaporated to dryness. The residue was taken up in water and extracted 3 times with dichloromethane (100 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and evaporate to dryness. The residue was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate (1:1) to give 7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-amine (1.50 g, 68%, 96% purity) as a light brown solid. MS: m / z = 264.1 [M+H] + .
[0324] gN-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester
[0325] To a stirred solution of 7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-amine (600 mg, 2.19 mmol, 96%) and phenyl chloroformate (1.81 g, 11.0 mmol, 95%) in THF (50 mL) was added K 2 CO 3 (1.59 g, 11.0 mmol, 95%) and pyridine (913 mg, 11.0 mmol, 95%). The mixture was stirred at 50° for 6 hours and then quenched by adding water (300 mL) after recooling to room temperature. The mixture was extracted 3 times with dichloromethane (200 mL), and the combined organic layers were washed once with brine (200 mL) and washed with anhydrous Na 2 SO 4 Dry, filter and evaporate to dryness under reduced pressure. This yields N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester (1.00 g, 69%, 76% purity) as a light yellow solid. The crude product was used directly in the next step without further purification. MS: m / z=504.1 [M+H] + .
[0326] hN-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide
[0327] To a mixture of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester (1.00 g, 1.52 mmol, 76.) and bis(7-oxa-2-azaspiro[4.5]decane), oxalic acid (1.19 g, 3.03 mmol, 95%) in THF (50 mL) was added diisopropylethylamine (1.24 g, 9.09 mmol, 95%) at room temperature under nitrogen atmosphere. The mixture was stirred at 60° for 1 hour. After cooling to room temperature again, the mixture was extracted twice with dichloromethane (100 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and evaporate to dryness. The residue was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:1) to give N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (600 mg, 92%) as a white solid. HPLC: 99.9% purity, RT=1.17min.MS: m / z=431.1[M+H]+.1HNMR (300MHz, DMSO-d6) δ11.37(s,1H),7.95(s,1H),6.25(s,1 H), 4.30-4.29 (m, 2H), 3.99 (s, 3H), 3.89 (t, J = 5.4Hz, 2H), 3.61-3.29 (m, 8H), 2.55-2.51 (m, 2H), 1.82-1.54 (m, 6H).
[0328] i. (5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 24
[0329] and (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide 25
[0330] N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (450 mg, 1.044 mmol, 1 eq., 99.9%) was purified by chiral preparative HPLC (preparative HPLC-032, column: ChiralPak IA, 2*25 cm, 5 μm; mobile phase, dichloromethane:ethanol (20:80); detector, UV). This yielded (5R)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (178 mg, 39%) as a white solid. HPLC: 99.7% purity, RT (chirality) = 3.86 min, 100% ee. MS: m / z = 431.2 [M+H] +.1H NMR (400 MHz, DMSO-d6) δ 11.36 (s, 1H), 7.94 (s, 1H), 6.24 (s, 1H), 4.29-4.27 (m, 2H), 3.97 (s, 3H), 3.88 (t, J = 5.2 Hz, 2H), 3.51-3.19 (m, 8H), 2.55-2.50 (m, 2H), 1.83-1.53 (m, 6H) and (5S)-N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-7-oxa-2-azaspiro[4.5]decane-2-carboxamide (171 mg, 38%), as a white solid. HPLC: 99.8% purity, RT (chirality) = 5.23 min, 99.9% ee. MS: m / z = 431.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 11.35 (s, 1H), 7.94 (s, 1H), 6.24 (s, 1H), 4.29-4.28 (m, 2H), 3.99 (s, 3H), 3.88-3.85 (m, 2H), 3.61-3.29 (m, 8H), 2.55-2.50 (m, 2H), 1.83-1.53 (m, 6H).
[0331] 2. N-[7-(3-aminophenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide 39
[0332]
[0333] jN-[3-(2-Benzamido-4-methoxy-1,3-benzothiazol-7-yl)phenyl]carbamate
[0334] To a solution of N-(7-iodo-4-methoxy-1,3-benzothiazol-2-yl)benzamide (400 mg, 0.878 mmol, 90%) and (3-[[(tert-butoxy)carbonyl]amino]phenyl)boronic acid (328 mg, 1.32 mmol, 95%) in 1,4-dioxane and water was added NaOH (369 mg, 8.78 mmol, 95%) and Pd(dppf)Cl2*dichloromethane (113 mg, 0.132 mmol, 95%) under an inert nitrogen atmosphere. After stirring at 100° C. under a nitrogen atmosphere overnight, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate (0-100%, 40 minutes) to give tert-butyl N-[3-(2-benzamido-4-methoxy-1,3-benzothiazol-7-yl)phenyl]carbamate (390 mg, 86%, 92% purity) as a yellow solid. MS: m / z = 477.0 [M+H] + .
[0335] kN-[3-(2-amino-4-methoxy-thiazolo[4,5-c]pyridin-7-yl)phenyl]carbamic acid tert-butyl ester
[0336] To a stirred solution of tert-butyl N-(3-[2-benzamido-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl)carbamate (390 mg, 0.753 mmol, 92%) in MeOH was added dropwise NaOH (318 mg, 7.55 mmol, 95%) dissolved in water (10 mL) at room temperature. The mixture was stirred at 90°C overnight, concentrated in vacuo, and the aqueous layer was extracted three times with dichloromethane (30 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 Drying. After filtration, the filtrate was concentrated to dryness under reduced pressure to produce tert-butyl N-[3-(2-amino-4-methoxy-thiazolo[4,5-c]pyridin-7-yl)phenyl]carbamate (220 mg, 54%, 69% purity) as a yellow solid. The crude product was used directly in the next step without further purification. MS: m / z = 372.9 [M+H] +.
[0337] lN-[7-(3-[[(tert-butyloxy)carbonyl]amino]phenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester
[0338] To tert-butyl N-(3-[2-amino-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl)carbamate (220 mg, 0.405 mmol, 69%) and K 2CO 3 To a stirred mixture of phenyl chloroformate (294 mg, 2.02 mmol, 95%) in THF (15 mL) was added dropwise phenyl chloroformate (333 mg, 2.02 mmol, 95%) and pyridine (168 mg, 2.02 mmol, 95%) at room temperature under nitrogen atmosphere. The mixture was stirred at 50° for another 4 hours. The reaction mixture was concentrated in vacuo, diluted with water (30 mL), and extracted 3 times with dichloromethane (30 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure to give N-[7-(3-[[(tert-butyloxy)carbonyl]amino]phenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester (350 mg, 74%, 52% purity) as a yellow solid. The crude product was used directly in the next step without further purification. MS: m / z=613.3[M+H]+.
[0339] mN-[4-methoxy-7-(1-methyl-1H-pyrazol-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-4-(methoxymethyl)benzamide, 14
[0340] To a stirred mixture of phenyl N-[7-(3-[[(tert-butoxy)carbonyl]amino]phenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (350 mg, 0.297 mmol, 52%) and 8-oxa-2-azaspiro[4.5]decane hydrochloride (111 mg, 0.594 mmol, 95%) in THF at room temperature under nitrogen atmosphere was added diisopropylethylamine (242 mg, 1.78 mmol, 95%) dropwise. The mixture was stirred at 60° overnight and then concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:1) to give tert-butyl N-[3-[4-methoxy-2-([8-oxa-2-azaspiro[4.5]decane-2-carbonyl]amino)-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl]carbamate (176 mg, 89%, 81% purity) as a yellow solid. MS: m / z=540.3[M+H]+.
[0341] nN-[7-(3-aminophenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide39
[0342] To a stirred mixture of tert-butyl N-[3-[4-methoxy-2-([8-oxa-2-azaspiro[4.5]decane-2-carbonyl]amino)-[1,3]thiazolo[4,5-c]pyridin-7-yl]phenyl]carbamate (176 mg, 0.264 mmol, 81%) in MeOH at 0 °C was added dropwise a 4N HCl solution in 1,4-dioxane (2.00 mL, 8.00 mmol, 95%). The mixture was stirred at room temperature for another 2 hours, concentrated to dryness and purified by preparative HPLC (2# SHIMADZU (HPLC-01), column: XBridge PrepOBD C18 column, 30x150mm 5μm; mobile phase: water / ACN (30% phase B until 60%, 8 min); detector, 254UV) to give N-[7-(3-aminophenyl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (60.0 mg, 80%, 99% purity) as a white solid. HPLC: 99.0% purity, RT=3.19min.MS: m / z=440.1[M+H]+.1H NMR (400MHz, DMSO-d6, ppm): 11.31 (s, 1H), 7.93 (s, 1H), 7.16 (t, J = 7.8Hz, 1H), 6.84 (t, J = 2.0Hz, 1H), 6.78-6. 73(m,1H),6.66-6.59(m,1H),5.30(s,2H),4.02(s,3H),3.69-3.44(m,4H),1.81(s,2H),1.50(t,J=5.4Hz,4H).
[0343] 3. N-(6-Fluoro-4-methoxy-7-tetrahydropyran-4-yl-thiazolo[4,5-c]pyridin-2-yl)-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
[0344]
[0345] oN-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide
[0346] In a 500 mL round bottom flask, to a solution of N-[7-(3,6-dihydro-2H-pyran-4-yl)-4-methoxy-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (4.10 g, 9.90 mmol, 89%) in 100 mL MeOH under nitrogen atmosphere was added Pd / C (10%, 19.6 g). The mixture was stirred at 50 °C for 3 days under hydrogen atmosphere, filtered through a celite pad and concentrated to dryness under reduced pressure. The residue was purified by silica gel column chromatography eluting with petroleum ether / ethyl acetate (1:1) to give N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.60 g, 54%, 76% purity) as a yellow solid. MS: m / z = 370.1 [M+H]+.
[0347] pN-[6-Bromo-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide
[0348] Into a 50 mL round-bottom flask was placed N-[4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.60 g, 5.34 mmol, 76%), N-bromo-succinimide (1.20 g, 6.40 mmol, 95%) / DMF (30 mL). The resulting solution was stirred at room temperature for 18 hours. The reaction was then terminated by the addition of water and concentrated to dryness. The residue was applied to a silica gel column with ethyl acetate / petroleum ether (0-50%) to give N-[6-bromo-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.50 g, 92%, 88 purity) as a yellow solid. MS: m / z=449.1[M+H]+.
[0349] qN-[4-methoxy-7-(oxan-4-yl)-6-(trimethylstannyl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide
[0350] Into a 50 mL pressure tank reactor purged and maintained with a nitrogen inert atmosphere were placed N-[6-bromo-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.50 g, 4.92 mmol, 88%), Pd(PPh 3 ) 4(1.44 g, 1.18 mmol, 95%) and hexamethyldistanane (1.70 g, 4.92 mmol, 95%) / dioxane (35 mL). The resulting mixture was stirred at 110 ° C for 1 hour. The reaction was then terminated by adding water and concentrated to dryness. The residue was applied to a silica gel column with ethyl acetate / petroleum ether (0-50%). This gave 2.30 g (70%, 79% purity) of N-[4-methoxy-7-(oxacyclohexane-4-yl)-6-(trimethylstannyl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide as a white solid. MS: m / z=449.1[M+H]+.
[0351] rN-[6-Fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide
[0352] In a 100 mL round-bottom flask, N-[4-methoxy-7-(oxan-4-yl)-6-(trimethylstannyl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (2.30 g, 3.43 mmol, 79%), (2.56 g, 6.85 mmol, 95%) / acetonitrile (50 mL). The resulting solution was stirred at room temperature for 18 hours. The reaction was then terminated by adding water and concentrated to dryness. The residue was applied to a silica gel column with ethyl acetate / hexane (0-50%). This gave 1.50 g (91%, 81% purity) of N-[6-fluoro-4-methoxy-7-(oxacyclohexane-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide as a white solid. MS: m / z=388.1[M+H]+.
[0353] s.6-Fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-amine
[0354] Into a 20 mL sealed tube purged and maintained with an inert atmosphere of nitrogen was placed N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]benzamide (1.50 g, 3.12 mmol, 81%) in MeOH (20 mL). NaOH (1.27 g, 31.2 mmol, 98%) dissolved in water (20 mL) was added at room temperature and the resulting solution was stirred at 100 °C for 16 hours. The resulting mixture was concentrated and the aqueous solution was extracted three times with 100 mL of dichloromethane. After filtration, the filtrate was evaporated to dryness and used without further purification to give 6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-amine (320 mg, 32%, 89% purity) as an off-white solid. MS: m / z = 284.1 [M+H]+.
[0355] tN-[6-Fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester
[0356] To 6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-amine (25 mg, 0.078 mmol, 89%) and K 2 CO 3 To a mixture of phenyl chloroformate (56.9 mg, 0.391 mmol, 95%) in THF (3.00 mL) was added dropwise phenyl chloroformate (64.5 mg, 0.391 mmol, 95%) and pyridine (32.6 mg, 0.391 mmol, 95%) at room temperature. The resulting mixture was stirred at 50 ° C for 6 hours under a nitrogen atmosphere. Water (10 mL) was added to terminate the reaction, and the resulting mixture was extracted twice with dichloromethane (10 mL). The combined organic layer was washed with brine (10 mL) and washed with anhydrous Na 2 SO 4 Dry, filter and evaporate to dryness under reduced pressure to give N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamate (60.0 mg, 73%, 50% purity). The crude product was used directly in the next step without further purification. MS: m / z=524.1[M+H]+.
[0357] uN-[6-Fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
[0358] To a mixture of N-[6-fluoro-4-methoxy-7-(oxan-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-N-(phenoxycarbonyl)carbamic acid phenyl ester (50 mg, 0.047 mmol, 50%) and 8-oxa-2-azaspiro[4.5]decane hydrochloride (26.5 mg, 0.142 mmol, 95%) in THF (3.00 mL) was added diisopropylethylamine (38.6 mg, 0.284 mmol, 95%) at room temperature. The resulting mixture was stirred at 60 ° C for 16 hours under nitrogen atmosphere. The mixture was diluted with water (10 mL) and extracted 3 times with dichloromethane (10 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and evaporate to dryness under reduced pressure. The crude product was purified by preparative HPLC (2# SHIMADZU (HPLC-01): column: XBridge Prep OBD C18 30x150mm, 5μm; mobile phase: water / acetonitrile, detector: UV). This produced N-[6-fluoro-4-methoxy-7-(oxacyclohexane-4-yl)-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (12.4 mg, 57%) as a light yellow solid. HPLC: 97.9% purity, RT=5.93min.MS: m / z=451.2[M+H]+.1HNMR (400MHz, DMSO-d6, ppm): 11.31 (s, 1H), 3.99-3.94 (m, 5H) ,3.61-3.45(m,10H),3.12(t,J=12.4Hz,1H),2.03(q,J=12.5Hz,2H),1.82(s,2H),1.65-1.62(m,2H),1.50(s,4H).
[0359] 4. N-[5-(Difluoromethyl)-4-oxo-7-phenyl-5λ4-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
[0360]
[0361] v N-[4-Hydroxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
[0362] In a 25 mL round-bottom flask, N-[4-methoxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (200 mg, 0.458 mmol, 97%) in dichloromethane (8 mL) was placed. BBr was added dropwise at 0°C. 3 (0.138 mL, 0.138 mmol, 1 M / dichloromethane), and the resulting solution was stirred at 0°C for another 2 hours. The reaction was then terminated by adding ice water. The mixture was extracted 3 times with dichloromethane (10 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and evaporate to dryness under reduced pressure. The residue was applied to a silica gel column with dichloromethane / methanol (0-30%) to give 150 mg (78%, 98% purity) of N-[4-hydroxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide as a white solid. MS: m / z=411.2[M+H]+.
[0363] w N-[5-(Difluoromethyl)-4-oxo-7-phenyl-5λ4-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide
[0364] Into a 50 mL sealed tube purged and maintained with a nitrogen inert atmosphere were placed N-[4-hydroxy-7-phenyl-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (100 mg, 0.238 mmol, 98%), anhydrous Na 2 SO 4 (3.37 mg, 0.024 mmol, 98%) / acetonitrile (5 mL). 2,2-difluoro-2-(fluorosulfonyl)acetic acid (50.8 mg, 0.285 mmol, 98%) was added to the mixture at room temperature, and the resulting solution was stirred for another 3 hours at room temperature. The reaction was then terminated by adding water (20 mL). The mixture was extracted 3 times with dichloromethane (10 mL). The combined organic layers were washed with anhydrous Na 2 SO 4Dry, filter and evaporate to dryness under reduced pressure. The crude product was purified by preparative HPLC (2# SHIMADZU (HPLC-01): column; Xselect CSH OBD column 30*150mm, 5μm, mobile phase: water / acetonitrile; detector: UV). This produced N-[5-(difluoromethyl)-4-oxo-7-phenyl-5λ4-[1,3]thiazolo[4,5-c]pyridin-2-yl]-8-oxa-2-azaspiro[4.5]decane-2-carboxamide (20.0 mg, 17%) as a white solid. Mp=225-226℃. HPLC: 95.1% purity, RT=6.27min.MS: m / z=461.2[M+H]+.1H NMR(400MHz,DMSO-d6,ppm)11.57(s,1H),8.08(d,J=8.6Hz,1H),7.89(s,1H),7.72(d,J=7.9Hz,2 H), 7.54 (dt, J = 32.6, 7.5Hz, 3H), 3.52 (s, 7H), 3.30 (s, 1H), 1.81 (d, J = 38.2Hz, 2H), 1.50 (s, 4H).
[0365] Example 3: Testing the inhibitory activity of the compounds of the present invention on human adenosine receptors in recombinant cells
[0366] Person A 2A , A 2B , A 1 and A 3 The functional activity of the receptors was determined by quantification of cAMP, a second messenger of adenosine receptors. 2A or A 2B HEK293 cells recombinant with the receptor (both Gs coupled were seeded into 394-well microtiter plates), test compounds and agonists (NECA) were incubated for 15 min, HTRF reagent (cAMP dynamic 2, Cis Bio) was added, and cellular cAMP levels were measured using an ENVISION (Perkin Elmer) plate reader.
[0367] For person A 1 and A 3 receptor, using expression A 1 or A 3 Since both receptors were coupled to Gi proteins, the assay protocol was adjusted:
[0368] Cells were seeded into 384-well plates and forskolin, test compounds and agonists (for A 1 -Receptor uses CPA, for A 3- receptor using IB-MECA). After 30 min of incubation, HTRF reagent (cAMP dynamic 2, Cis Bio) was added and cellular cAMP levels were measured using an ENVISION (Perkin Elmer) plate reader.
[0369] The resulting raw data were normalized to inhibitor control and neutral control (DMSO), and the normalized data were fitted using GeneData software.
[0370] Relative to adenosine A 1 and A 3 The compounds of the present invention show adenosine A receptor 2A and A 2B High selectivity for receptors (see for example Table 4 for data on some examples of compounds of the invention).
[0371] Specifically, compared with the known adenosine A 2A The receptor antagonist Tozadenant and similar benzothiazole derivatives (see Table 5) are very different. The compounds of the present invention surprisingly show A 2A / A 2B dual activity (see Table 4), which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above; or the compounds of the present invention show at least a high A 2A The inhibitory activity, together with other surprising advantages disclosed herein, results in high efficacy in the treatment and / or prevention of hyperproliferative and infectious diseases and disorders.
[0372] Table 4 - Compounds of the Invention
[0373]
[0374]
[0375]
[0376]
[0377]
[0378] A stands for IC 50 Value <10nM, B indicates IC 50 Values < 100 nM, C represents IC 50 Values < 1 μM, D represents IC 50 Values >1 μM.
[0379] Table 5 - Prior art compounds specifically disclosed in WO2005 / 028484 and WO2005 / 000842
[0380]
[0381]
[0382]
[0383]
[0384]
[0385] A stands for IC 50 Value <10nM, B indicates IC 50 Values < 100 nM, C represents IC 50 Values < 1 μM, D represents IC 50 Values >1 μM.
[0386] Example 4: Testing the effects of the compounds of the present invention on endogenous human A 2A The role of receptors
[0387] Determination of Gs-coupled human A in T cells 2A Endogenous functional activity of a receptor that is highly expressed in T cells. Receptor activity is measured by quantifying cAMP, a second messenger for adenosine receptors.
[0388] Briefly, human pan T cells were isolated from human PBMCs derived from fresh whole blood (MACS Pan T Cell Isolation Kit, Miltenyi Biotec). T cells were seeded in 384-well microtiter plates and treated with test compounds. After incubation at room temperature for 10 min, A 2A The adenosine receptor agonist CGS-21680 was added and the plates were incubated for another 45 min. Finally, HTRF reagent (cAMP Femto kit, CisBio) was added to the wells and cellular cAMP levels were determined after 1 h using an ENVISION (Perkin Elmer) plate reader.
[0389] The resulting raw data were normalized to inhibitor controls and neutral controls (DMSO), and the normalized data were fit using GenedataScreener software.
[0390] The compounds of the present invention show that they are able to inhibit the 2A Adenosine receptor agonist CGS-21680 expressed in human T cells 2AReceptors (as measured by quantification of cAMP), which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above. Thus, the compounds of the present invention are surprisingly able to prevent immunosuppression and thus are able to support the inhibition of tumor growth induced by anti-tumor T cells, the reduction or destruction of metastasis, and the prevention of neovascularization.
[0391] Example 5: Pharmacokinetic properties of compounds of the invention in experimental rats and mice
[0392] The aim of this study was to obtain information on the pharmacokinetic properties of compounds of the invention in female Wistar rats / mice following single intravenous and oral administration.
[0393] Materials and methods
[0394] Animal Testing (Life Stage)
[0395] Female Wistar rats / mice (n=6) received a single intravenous (bolus) injection or oral administration (by gavage) of the test compound. Doses of 0.2 and 10 mg / kg (each compound) were administered intravenously and orally, respectively, as a solution in DMSO (0.2%) / PEG 200 (40%) / water for intravenous administration and as a suspension in Methocel (0.5%) / Tween 20 (0.25%) aqueous solution for oral administration. Serial blood samples were obtained sublingually under isoflurane inhalation from 3 animals per route of administration after 0.1 (only intravenous injection), 0.25 (only oral administration), 0.5, 1, 2, 4, 6 and 24 h and further processed to obtain plasma. Similarly, urine and feces samples were collected from 3 rats per route of administration at intervals of 0-24 h and combined for analysis.
[0396] Biological analysis:
[0397] The concentrations of compounds in plasma and feces were quantified using a UPLC method with tandem mass spectrometry detection (LC-MS / MS) previously developed at the Institute of Drug Metabolism and Pharmacokinetics. The LC-MS / MS system consisted of a Waters Acquity UPLC coupled to an AB Sciex mass spectrometer API 5500 Q-trap. UPLC separations were performed on a reverse phase column (HSS T3, 1.8 μM, 2.1×50 mm) using 0.1% formic acid and acetonitrile as eluents with a mobile phase gradient. Compounds were detected using multiple reaction monitoring in positive ionization mode. Plasma samples were spiked with internal standards (20 μl) and analytes were extracted from the matrix with tert-butyl methyl ether (tBME). The organic phase was evaporated to dryness under a nitrogen stream. The residue was dissolved in acetonitrile / 0.1% formic acid for LC-MS / MS analysis. Fecal samples were homogenized with 4 times their volume of an ethanol / water mixture (4:1, v / v). An aliquot of the water-ethanol extract was spiked with internal standards, diluted with acetonitrile / water (1:1, v / v), and directly injected into the LC-MS / MS system.
[0398] Pharmacokinetic Assessment:
[0399] Obtaining pharmacokinetic parameters C from observed data max and t max The area under the curve (AUC), clearance (CL), volume (V), half-life (t 1 / 2 ), F and all dose normalized values. The "DDS-TOX" values of several compounds were evaluated and shown to be comparable to the values given by the validated software WinNonLin. AUC values were calculated by non-compartmental analysis using a linear up / log down method. Numerical data for mean plasma concentrations and derived pharmacokinetic parameters were rounded to 3 significant figures for expression. Oral bioavailability and excretion data (expressed as % of dose) were displayed with 2 significant figures.
[0400] Adenosine A 2A Compared to the receptor antagonist Tozadenant and similar benzothiazole derivatives, the compounds of the present invention surprisingly show better pharmacokinetic properties in mice as an animal model associated with cancer (see Table 6), which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above.
[0401] Table 6
[0402]
[0403] Example 6: Testing the effect of the compounds of the present invention on mouse T cells
[0404] background:
[0405] Adenosine (Ado) in the tumor microenvironment can be activated by A 2A A suppresses T cell activity by inhibiting the signaling of the receptor and suppresses the secretion of cytokines by T cells. 2A Specific agonists, such as NECA, do a similar job of inhibiting cytokine secretion from T cells in vitro and in vivo. 2A Antagonist or A 2A / A2B Dual antagonists rescue T cells from this suppression. Here, we describe our established in vitro system for screening potential A-cells for their activity using Pan T cells from mouse spleen. 2A Antagonist or A 2A / A 2B Dual antagonists. The method involves stimulating PanT cells purified from mouse spleen cells with CD3 / CD28 pre-coated beads to bind to potential A 2A or A 2A / A 2B Dual antagonists together with A 2A The addition of agonists was combined to assess the enhancement of T cell cytokine production.
[0406] mTcell analysis, cAMP, analysis instructions:
[0407] Pan T cells were isolated from Black 6 mice by manual dissociation and purified using the Miltenyi Pan T Cell Isolation Kit. Isolated T cells were activated in 96-well plates for 48 hours using anti-CD3 / CD28 beads in T cell proliferation medium.
[0408] After 48 hours, T cells were pooled, counted and suspended in serum-free medium containing 0.1% BSA. Cells were seeded in 10ul medium at 50,000 cells per well and incubated at 37°C for 2 hours. Test compounds were distributed to the wells in a 10-point dose response with a starting concentration of 10uM. After adding the compounds, the agonist NECA was added to all wells at a concentration of 1uM. The plates were incubated at 37°C for 30 minutes and cAMP levels were analyzed using the Cisbio cAMP Dynamic2 kit by adding 10ul of the kit reagent to each well. The plates were incubated at room temperature for 1 hour and the HTRF signals were read on the Envision plate reader. The raw data was analyzed in Genedata Screener and the resulting data was loaded into the database.
[0409] mTcell analysis, IL-2, analysis description:
[0410] Briefly, mouse Pan T cells were purified from spleens of BALB / c mice using the Pan T Cell Isolation Kit Mouse II (MACS Miltenyibiotech Catalog Order No. 130-095-130) according to the manufacturer's protocol. The purified T cells were inoculated in Nunc TM The cells were placed in RPMI medium with 10% heat-inactivated fetal bovine serum in a 96-well polystyrene round-bottom microplate. After the cells were allowed to rest for 1 h at 37°C, they were incubated with CD3 / CD28 pre-coated beads (Dynabeads TM Mouse T-Activator CD3 / CD28; Cat#11456D). After 30 min, cells were treated with different doses of test antagonists. After incubation at 37°C for another 30 min, cells were treated with A 2A The cells were treated with NECA (1 μM) or a neutral control (DMSO). IL-2 levels in the supernatant after 24 h of incubation were determined by ELISA according to the manufacturer's protocol (R&Dsystems Cat# DY402 (IL-2)). Once the concentrations were calculated, the difference between the cytokine concentrations of the DMSO control and the agonist alone control was calculated, and the percent rescue for each antagonist concentration was calculated using Microsoft Excel. These percent rescues of cytokines were plotted in a dose-dependent manner for the antagonists in GraphPad Prism software, and the IC 50 .
[0411] Adenosine A 2A The compounds of the present invention are quite different from the receptor antagonist Tozadenant and similar compounds (see Table 8), and they show that they can rescue T cells from suppression and can prevent the inhibition of T cells by adenosine or A 2A Inhibition of cytokine secretion induced by specific agonists (e.g., NECA) (see Table 7), which is preferred for the treatment and / or prevention of hyperproliferative and infectious diseases and disorders, as disclosed above. Thus, the compounds of the present invention are surprisingly able to prevent immunosuppression and thus are able to support the inhibition of tumor growth induced by anti-tumor T cells, the reduction or destruction of metastasis, and the prevention of neovascularization.
[0412] Table 7 - Compounds of the Invention
[0413]
[0414]
[0415]
[0416]
[0417]
[0418] A stands for IC 50 Value <10nM, B indicates IC 50 Values < 100 nM, C represents IC 50 Values < 1 μM, D represents IC 50 Values >1 μM.
[0419] Table 8 - Prior art compounds specifically disclosed in WO2005 / 028484 and WO2005 / 000842
[0420]
[0421]
[0422]
[0423] A stands for IC 50 Value <10nM, B indicates IC 50 Values < 100 nM, C represents IC 50 Values < 1 μM, D represents IC 50 Values >1 μM.
[0424] Example 7: Testing the effect of the compounds of the present invention on human T cells
[0425] Gs-coupled human A was measured in T cells 2A Endogenous functional activity of the receptor, which is highly expressed in T cells. Receptor activity is measured by quantification of cAMP, a second messenger for adenosine receptors.
[0426] Analysis
[0427] Briefly, human pan T cells were isolated from human PBMCs derived from fresh whole blood (MACS Pan T Cell Isolation Kit, Miltenyi Biotec). T cells were seeded in 384-well microtiter plates and treated with test compounds. After incubation at room temperature for 10 minutes, A 2A The adenosine receptor agonist NECA was added and the plates were incubated for an additional 45 minutes. Finally, HTRF reagent (cAMPFemto Kit, CisBio) was added to the wells and cellular cAMP levels were measured 1 hour later using an ENVISION (Perkin Elmer) plate reader.
[0428] The raw data obtained were normalized to inhibitor controls and neutral controls (DMSO), and the normalized data were fitted using Genedata Screener software.
[0429] The compounds of the present invention show that they can inhibit 2A Adenosine receptor agonist NECA expressed in human T cells 2A Receptors (measured by quantification of cAMP), which is preferred for the treatment and / or prevention of the hyperproliferative and infectious diseases and disorders disclosed above. Thus, the compounds of the present invention are surprisingly able to prevent immunosuppression and thus are able to support anti-tumor T cell-induced tumor growth inhibition, reduction or destruction of metastasis and prevention of neovascularization.
[0430] Table 9 - Compounds of the Invention
[0431]
[0432]
[0433]
[0434]
[0435]
[0436]
[0437]
[0438] A stands for IC 50 Value <10nM, B indicates IC 50 Values < 100 nM, C represents IC 50 Values < 1 μM, D represents IC 50 Values >1 μM.
[0439] Table 10 - Prior art compounds specifically disclosed in WO2005 / 028484 and WO2005 / 000842
[0440]
[0441]
[0442]
[0443] A stands for IC 50 Value <10nM, B indicates IC 50 Values < 100 nM, C represents IC 50 Values < 1 μM, D represents IC50 Values >1 μM.
[0444] Example 8: Injection Vial
[0445] A solution of 100 g of the compound of the present invention and 5 g of disodium hydrogen phosphate in 3 l of double distilled water was adjusted to pH 6.5 with 2N hydrochloric acid, filtered under aseptic conditions, transferred into injection vials, lyophilized under aseptic conditions, and sealed under aseptic conditions. Each injection vial contained 5 mg of the compound of the present invention.
[0446] Example 9: Solution
[0447] From 1 g of the compound of the present invention, 9.38 g of NaH 2 PO 4 ·2H 2 O, 28.48gNa 2 HPO 4 12H 2 A solution of 100 μl of 1% ethanol and 0.1 g of benzalkonium chloride was prepared in 940 ml of double distilled water. The pH was adjusted to 6.8, the solution was made up to 1 l and sterilized by irradiation.
[0448] Example 10: Ampoule
[0449] A solution of 1 kg of the compound of the present invention in 60 L of double distilled water was filtered under sterile conditions, transferred into ampoules, lyophilized under sterile conditions, and sealed under sterile conditions. Each ampoule contained 10 mg of the compound of the present invention.
Claims
1. A compound selected from the group consisting of: and their physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios.
2. The use of a compound according to claim 1 or a physiologically acceptable salt or stereoisomer thereof, or a mixture thereof in all ratios, for the preparation of a medicament as adenosine A 2A and / or A 2B Receptor inhibitors.
3. Pharmaceutical preparations comprising at least one compound according to claim 1 and / or its physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios.
4. The pharmaceutical preparation according to claim 3, comprising other excipients and / or adjuvants.
5. Pharmaceutical preparation comprising at least one compound according to claim 1 and / or its physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios; and at least one further pharmaceutically active compound.
6. A method for preparing a pharmaceutical preparation, Features The compounds according to claim 1 and / or their physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios, are brought into suitable dosage forms together with solid, liquid or semiliquid excipients or adjuvants.
7. Medicament comprising at least one compound according to claim 1 and / or one of its physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios, for the treatment and / or prevention of physiological and / or pathophysiological conditions.
8. Medicament comprising at least one compound according to claim 1 and / or one of its physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios, for the treatment and / or prevention of physiological and / or pathophysiological conditions selected from the group consisting of hyperproliferative and infectious diseases and disorders.
9. The medicament according to claim 8, wherein the hyperproliferative disease or disorder is cancer.
10. The medicament according to claim 9, wherein the cancer is selected from the group consisting of acute and chronic lymphocytic leukemia, acute myeloid leukemia, adrenocortical carcinoma, bladder cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, chronic myeloid leukemia, colon cancer, endometrial cancer, esophageal cancer, essential thrombocythemia, glioma, glioblastoma, hairy cell leukemia, head and neck cancer, Hodgkin's disease, Kaposi's sarcoma, lung cancer, lymphoma, malignant hypercalcemia, malignant pancreatic insulinoma, medullary thyroid cancer, melanoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin's lymphoma, osteogenic sarcoma, ovarian cancer, pancreatic cancer, polycythemia vera, essential macroglobulinemia, prostate cancer, renal cell carcinoma, rhabdomyosarcoma, skin cancer, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, testicular cancer, thyroid cancer and Wilms' tumor.
11. The medicament according to claim 10, wherein the melanoma is malignant melanoma, the lung cancer is small cell lung cancer or non-small cell lung cancer, and the brain cancer is primary brain cancer.
12. The medicament according to claim 8, wherein the hyperproliferative disease or disorder is selected from age-related macular degeneration, Crohn's disease, cirrhosis, chronic inflammation-related disorders, proliferative diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, granulomatous diseases, immune hyperproliferation associated with organ or tissue transplantation, and an immunoproliferative disease or disorder selected from inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), vascular hyperproliferation secondary to retinal hypoxia, and vasculitis.
13. The medicament according to claim 8, wherein the infectious disease or disorder is selected from: i. a virus-induced infectious disease caused by a retrovirus, a hepadnavirus, a herpesvirus, a Flaviviridae and / or an adenovirus, wherein the retrovirus is selected from a lentivirus or an oncorretrovirus, wherein the lentivirus is selected from HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV and EIAV, and the oncorretrovirus is selected from HTLV-I, HTLV-II and BLV, the hepadnavirus is selected from HBV, GSHV and WHV, the herpesvirus is selected from HSV I, HSV II, EBV, VZV, HCMV or HHV 8, and the Flaviviridae is selected from HCV, West Nile virus and yellow fever virus, ii. a bacterial infectious disease caused by a gram-positive bacterium, wherein the gram-positive bacterium is selected from methicillin-sensitive and methicillin-resistant Staphylococci, glycopeptide-intermediate-sensitive Staphylococcus aureus, penicillin-sensitive and penicillin-resistant Streptococci, Enterococci, Clostridium difficile, Listeria monocytogenes, Corynebacterium jejuni, Chlamydia spp. and Mycobacterium tuberculosis, iii. bacterial infectious diseases caused by Gram-negative bacteria, wherein the Gram-negative bacteria are selected from the family Enterobacteriaceae, including Escherichia, Klebsiella, Enterobacter, Citrobacter, Serratia, Proteus, Providencia, Salmonella, Shigella, Pseudomonas, Moraxella, Haemophilus and Neisseria, iv. Infectious diseases caused by intracellular active parasites selected from the group consisting of Apicomplexa or Trichuris, Cryptosporidium, Sacrocystida, Amebas, Coccidia and Trichomonas.
14. The medicament according to claim 13, wherein the Gram-positive bacteria are selected from Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus, coagulase-negative Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sanguinis, Group C Streptococcus, Group G Streptococcus, Viridans Streptococcus, Enterococcus faecalis, Enterococcus faecium and Chlamydia pneumoniae; the Gram-negative bacteria are selected from Escherichia coli, Pseudomonas aeruginosa and Moraxella catarrhalis; and the intracellular active parasites are selected from Trypanosoma, Plasmodium, Leishmania, Babesia and Theileria.
15. A set consisting of the following individually packaged items: a) an effective amount of a compound according to claim 1 and / or its physiologically acceptable salts and stereoisomers, and mixtures thereof in all ratios, and b) an effective amount of another pharmaceutically active compound.
Citation Information
Patent Citations
Method and apparatus for automated classification and analysis of cells
US4125828A
Method and apparatus for automated classification and analysis of cells
US4207554A
Quinazoline derivatives
WO1997022596A1
Quinazoline derivatives as VEGF inhibitors
WO1997030035A1
4-anilinoquinazoline derivatives
WO1997032856A1
